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Abstract
Prostate cancer is the most common cancer among American men, the third highest
mortality rate. Current treatment options consist of androgen deprivation therapies, actual or
chemical castration, and the use of androgen blockers called anti-androgens. Ultimately the
disease advances to a hormone-independent state known as castration-resistant prostate cancer
(CRPC). The folding, activation, and nuclear translocation of steroid hormone receptors requires
the sequential action and cooperation of at least twelve proteins that make up four distinct
complexes. At least one of these proteins, the FKBP52 cochaperone, is a promising therapeutic
target for disrupting several mechanisms important in prostate cancer (PCa). FKBP52 is a
positive regulator of androgen (AR), glucocorticoid (GR), and progesterone receptor (PR)
hormone binding, nuclear translocation, and transcriptional activity. FKBP52 regulates multiple,
distinct steps within the AR signaling pathway, some of which are independent of Hsp90. The
direct targeting of FKBP52 will inhibit beta-catenin, FKBP51, and FKBP52-dependent
potentiation of AR activity, including PCa cell growth, in addition to inhibiting GR and PR
activity. Small molecules targeting FKBP52 would simultaneously hit multiple pathways known
to having a role in PCa. Data suggest that the proline-rich loop surface that overhangs the
FKBP52 PPIase pocket is important and likely represents an AR interaction surface. We aimed
to identify specific PPIase binding molecules that, when docked in the pocket, reorient the
proline-rich loop leading to the disruption of FKBP52 interactions.
To this end, we used structure-based drug design methodology in order to identify
molecules predicted to bind tightly to the FKBP52 PPIase pocket with high affinity. A primary
screen of the predicted hits identified GMC1, a molecule that inhibits explicitly FKBP52mediated AR, GR, and PR activity in reporter assays, AR-dependent gene expression in prostate

vii

cancer cells, AR-dependent proliferation of prostate cancer cells, and tumor growth in mouse
xenograft models. We are currently performing hit-to-lead optimization by screening rationally
designed GMC1 modifications to increase efficacy, reduce toxicity, and ensure bioavailability.
Independent of GMC1, an in silico structure-based drug design identified PC257, a unique
FKBP52-specific inhibitor that specifically inhibits FKBP52-mediated AR, GR, and PR activity
in reporter assays, AR-dependent gene expression in a variety of prostate cancer cell lines,
effectively abrogates AR-dependent proliferation in prostate cancer cells, alters full-length AR
signaling and nuclear translocation in WT 22RV1 cells and inhibits tumor growth in mouse
xenograft models. As a result, we have identified new leads from GMC1 SAR analysis and novel
FKBP52-specific hits from the in silico screens that will be further characterized in both cellular
and animal models of prostate cancer. We pursued the identification of drug combination
therapies using classic anti-androgens alongside beta-blockers to increase efficacy, reduce
toxicity and prolong drug resistance. We believe GMC1 and PC257 have the potential to be a
first-in-class drug that directly targets the FKBP52 cochaperone for the treatment of prostate
cancer, and drug combination therapy with beta-blockers will highlight the importance of current
drug resistance to anti-androgens in the early stages of prostate cancer.
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Chapter 1: Introduction
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1.1 PROSTATE CANCER
Other than skin cancer, prostate cancer is the most common cancer among American men
(1). According to the American Cancer Society, there are an estimated 248,530 new cases for
prostate cancer and roughly about 34,130 deaths projected in the United States for 2021, which
have drastically risen since 2017. Prostate cancer related deaths are typically the result of
metastatic disease that becomes life-threatening. For prostate cancer to survive and thrive, it
requires male hormones known as androgens. The androgen receptor regulated genes contribute
to the initiation and progression of prostate cancer. Therefore, initial therapies rely on androgen
deprivation therapies, actual or chemical castration, to prevent the testicles from supplying
androgens and use of androgen blockers called anti-androgens. Ultimately the disease can
progress to a hormone-independent state known as castration-resistant prostate cancer (CRPC).
In this hormone-independent state, the disease is still driven by the androgen receptor; it is just
either hyper-reactive to hormone, or it no longer needs hormone activation. As a result of
persistent AR signaling playing a pivotal role in disease progression, understanding AR structure
and signaling is crucial for developing novel CRPC therapies.
1.2 THE ROLE OF THE ANDROGEN RECEPTOR
The androgen receptor (AR) belongs to the steroid hormone receptor (SHR) family of
transcriptional regulators that coordinate the metabolic and differentiation functions (2–4). The
AR gene is located on the X chromosome and encodes for a 110 kDa protein consisting of 919
amino acids that extend eight exons (5–7). The exons are composed of 4 distinct domains: a
poorly conserved N-terminal domain (NTD), a highly conserved DNA binding domain (DBD), a
hinge region, and a ligand-binding domain (LBD).
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The poorly conserved N-terminal domain (NTD) is located on exon one and is
constitutively active. This domain contains an AF-1 site and is considered the main activation
domain for AR, including two transcriptional activation units TAU-1 and TAU-5 (8, 9). TAU-1
has a nuclear receptor box FQNFL, and TAU-5 is mediated through a WHTLF motif that
mediates ligand-dependent and interdomain interactions between the NTD and the LBD; these
interactions stabilize the AR dimer complex to slow the rate of ligand dissociation (5).
The highly conserved DNA binding domain (DBD) contains 68 amino acids located on
exons two and three (5, 8). It is a cysteine-rich region containing nine cysteines that are required
for high-affinity DNA binding (10). Within the DBD, two zinc fingers contain four cysteine
residues to assist in the folding of each zinc finger, the first zinc finger has a P-box motif that is
responsible for gene-specific contacts within the DNA groove, and the second zinc finger
contains a D-box motif, which acts as a DNA/DNA binding site for receptor homodimer
formation (5, 8, 10, 11).
The hinge region is considered a flexible linker that allows rotation of DNA and separates
the DNA binding domain from the ligand-binding domain. It contains a bipartile liganddependent nuclear localization signal (NLS) for AR nuclear import (8). The hinge region is
unique in that it plays a role in DNA binding, co-activator recruitment, and a target site for
acetylation, ubiquitylation, and methylation (5, 12, 13).
The ligand-binding domain (LBD) is responsible for binding ligand, interacting with heat
shock proteins, mediating homo-dimerization, hetero-dimerization, and ligand-dependent
transcriptional activity (5, 8, 10). The LBD contains 12 α-helical regions numbered from H1 to
H12; these helices fold into an antiparallel helical sandwich; within this sandwich, a cavity is
formed known as the ligand-binding pocket (LBP) to which ligand binds (10). Like the NTD, the
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LBD contains an AF2 region that serves as a docking site for co-regulators containing LxxLL
motifs (8, 14). The AF2 region acts as a lid to close the ligand-binding pocket; when agonist
(DHT) binds on the LBD, this leads to a ligand-dependent transcriptional activation in which a
conformational change takes place (5, 10, 15).
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Figure 1.2.1: Structure of the Androgen Receptor

The androgen receptor gene contains eight exons, which are composed of 4 major domains. The
N-terminal domain (NTD), DNA binding domain (DBD), a hinge region, and a ligand-binding
domain (LBD). The poorly conserved N-terminal domain is constitutively active and contains an
AF-1 function that activates AR due to its WxxLF motif. The highly conserved DNA binding
domain serves as a binding site for DNA and consists of two zinc fingers, a P-box motif, and a
D-box motif. The hinge region is a flexible linker that allows rotation of DNA and separates the
DBD from the LBD; within this region, a nuclear localization signal (NLS) is responsible for
ligand-dependent nuclear transport. The ligand-binding domain helps in the binding of AR
ligands such as testosterone and DHT. It also contains an AF-2 function that is responsible for
ligand-dependent transcriptional activation.
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1.3 CLASSIC ANDROGEN RECEPTOR SIGNALING
Androgens play a pivotal role in male sexual development, growth, and function of the
prostate. The androgen receptor activity is modulated by androgenic steroids, testosterone, and
dihydrotestosterone (DHT). Testosterone is produced by the testes in males and eventually is
converted to dihydrotestosterone by way of the 5α-reductase enzyme (6, 8). Although
testosterone can bind and activate AR, the prostate’s primary androgen is dihydrotestosterone
because it has a higher affinity for AR and activates the receptor at lower concentrations (6). The
androgen receptor is bound to the cytoplasm to heat shock proteins Hsp90 and p23. When DHT
binds to the ligand-binding pocket, a conformational change occurs within the LBD, and an AF-2
binding surface is formed (8). Consequently, the receptor disassociates from the heat shock
proteins, dimerizes, and translocates to the nucleus, where it binds to androgen response
elements (ARE) to recruit co-regulators and activate transcription of target genes to promote
growth and survival (6, 16).
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Figure 1.3.2: Androgen Receptor Signaling in Prostate Cancer

The androgen receptor is bound in the cytoplasm to heat shock proteins; when 5αdihydrotestosterone (DHT) binds to AR with high affinity, the heat shock proteins disengage
from AR, allowing translocation to the nucleus, dimerizes and attaches to the androgen response
elements (ARE) to initiate gene transcription to promote prostate cancer growth.
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1.4 ANDROGEN RECEPTOR CHAPERONE-MEDIATED MATURATION CYCLE
The androgen receptor is mediated by an assembly of co-activators and cochaperones that
help fold the receptor to reach a high-affinity binding conformation to bind hormone. The five
cochaperones necessary consist of Hsp40, Hsp70, Hsp90, Hop, and p23 (17). The receptor
begins its cycle by being translocated from the ribosomes to the cytoplasm, where it begins
associating with Hsp40 and later recruits Hsp70. At this stage, Hsp interacting protein (HIP) and
Hsp organizer protein (HOP) bind to Hsp70 in the efforts to recruit Hsp90; if binding does not
occur, the receptor will enter proteasomal degradation (17, 18). Proteasomal degradation will
happen if the ribosome has been missed folded. The proteins involved that direct the receptor
towards ubiquitin and proteasomal degradation pathways are CHIP and the carboxyl terminus of
BAG. Once the receptor has reached the intermediate state and has bound HIP, HOP, and Hsp90,
it moves onto a mature complex where immunophilins FKBP52, FKBP51, CyP40, and PP5
compete for binding to Hsp90 (17–19). Along with this process, p23 binds to stabilize Hsp90
interactions to reach a high-affinity binding conformation (17, 20, 21). These chaperones and
cochaperones go through a vigorous mediated cycle and are critical for folding and stabilizing
the receptor before hormone can bind.
1.4.1 Androgen Receptor Early Complex
In the early complex, the first step of the maturation process begins with the receptor
associating with Hsp40, which initiates the recruitment of Hsp70 binding to the receptor ligandbinding domain (LBD) (18, 22, 23). The receptor is bound to Hsp70 in an ATP-dependent
manner, in which Hsp40 stimulates Hsp70 ATPase activity (18). In this stage, a check and
balance system transpires to monitor the receptor’s folding in the cycle (18, 24). If folded
properly, the receptor will move on and continue the process to reach a high-affinity binding
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conformation. Conversely, if the receptor is determined to be folded incorrectly, it will enter
degradation through CHIP and BAG-1 proteins. The cochaperone CHIP binds to Hsp70 and
Hsp90 through their TPR domains and will inhibit chaperones’ folding by keeping the chaperone
in an ATP-bound conformational state (18, 24–26). Once determined to be incorrectly folded, the
receptor will stay in the chaperoning cycle until it is eventually ubiquitinated and targeted for
degradation (18, 27).
1.4.2 Androgen Receptor Intermediate Complex
Properly folded receptors continue onto the intermediate complex. Hsp70 interacts with
Hsp interacting (HIP) through its N-terminal TPR domain, which prevents ADP dissociation
from Hsp70 to enhance the receptor’s interaction with Hsp90 and HOP (18, 28–33). HOP
contains a TPR domain with conserved TPR-clamp domains embedded between Hsp90 dimer
and Hsp70 by binding to TPR2A and TPR1/TPR2B motifs that enable the client transfers
between the two chaperones (18, 28, 34–36). It is important to note that HOP binding to the TPR
acceptor site inhibits the other C-terminal TPR acceptor on the Hsp90 dimer to be bound (18).
Hsp90 contains an N-terminal domain (NTD), and its purpose is to bind ATP to induce
interaction between the N-terminal domain of the Hsp90 dimer (18, 37, 38).
1.4.3 Androgen Receptor Mature Complex
When the inhibition of Hsp90 ATPase activity is removed, ATPs bind and secure the
nucleotides by closing ATP lids; this conformational change in Hsp90 leads to the closing of
NTDs (18, 39, 40). As a result, HOP, HIP, and Hsp70 disassociate and allow ATPase homologue
1 (Aha1), an activator of Hsp90, to bind to the middle domain (MD) that assists in the
repositioning and interaction of NTDs (18, 37). At this point, p23 and TPR-containing PPIase
immunophilins are recruited (18, 41). P23 is a small acidic protein essential for chaperone
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activity; p23 binds to the closed conformation of Hsp90 and promotes the receptor’s maturation
by stabilizing the closed conformation of Hsp90 (18, 20, 41–45). In this active Hsp90/p23/TPRcontaining PPIase mature complex, the receptor binds with high-affinity (18). The receptor
remains in the cytoplasm and, upon ligand-binding, dimerizes, translocates to the nucleus, and
binds to hormone response elements (HRE) resulting in prostate cancer growth (18). If ligandbinding does not occur, then the Hsp90/p23/TPR-containing PPIase complex waits for the
breakdown of ATP and dissociation of NTDs of Hsp90 release p23 and TPR-containing PPIase,
leading to a nascent receptor re-entering the chaperone cycle (18, 46, 47).
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Figure 1.4.3: Chaperone-Mediated Maturation Cycle

In order for the androgen receptor to reach a high-affinity binding conformation, it must go
through a dynamic cycle of chaperone-mediated folding. It goes through a series of complexes,
and once it is done interacting with those complexes, it can now bind hormone. The ribosome
binds to Hsp40 and later in the early complexes recruits Hsp70. At this point, the ribosome can
continue to an intermediate complex that binds to HIP, HOP, and Hsp90 or the ribosome can be
led to proteasomal degradation. If the receptor is folded correctly, it will move forward to
intermediate complexes where Hsp70 recruits HIP and HOP forming a bridge so that Hsp90 can
bind. The receptor then allows for immunophilins (FKBP52, FKBP51, CyP40, PP5) to bind
competitively to Hsp90, when bound a conformational change occurs. As the mature complex
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begins to form, HIP, HOP, and Hsp70 dissociate. At this moment, p23 can bind to stabilize the
receptor Hsp90 complex, allowing hormone to bind with high affinity.
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1.5 THE ROLE OF FKBP52 CO-CHAPERONE
FKBP52 is a promising therapeutic target for the disruption of several mechanisms
important in PCa. FKBP52 is a positive regulator of androgen receptor (AR), glucocorticoid
receptor (GR), progesterone receptor (PR) and is responsible for male sexual differentiation and
development. FKBP52 regulates multiple distinct steps within the AR signaling pathway, some
of which are independent of Hsp90 (18, 48). FKBP52 has been identified as one of the
tetratricopeptide repeats (TPR)-containing proteins associated with the Hsp90 complex through
the C-terminal (18, 49). Besides associating with Hsp90 and p23, FKBP52 belongs to a family of
immunophilins along with FKBP51, PP5, and CyP40. The cochaperone contains a conserved
PPIase domain, which has a peptidyl-prolyl cis/trans isomerase activity that serves as a binding
site for immunosuppressive drug FK506 (18, 50). The protein is composed of four distinct
domains consisting of a C-terminal Hsp90 binding TRP domain, an N-terminal FK1 domain that
contains a functional peptidyl /prolyl isomerase (PPIase) active site to which the
immunosuppressive drug FK506 binds, an FK linker that connects the FK1 domain to FK2 and
an FK2 domain that is like FK1 but lacks PPIase activity (51).
1.5.1 TPR Domain
The TPR domain contains 136 amino acids composed of three 34 amino acid motif
repeats (18). The motifs assume a helix-loop-helix conformation, forming parallel open binding
pocket stacks that mediate protein-protein interactions (18, 52–54). Once motifs have taken
form, TPR domains interact with the MEEVD pentapeptide sequence in the extreme C-terminus
of Hsp90 (18). The extreme C-terminus is located outside the TPR domain and contains a 20
amino acid consensus motif essential in Hsp90 binding (18, 55). A conserved region moderates
binding to Hsp90 termed Charge-Y, which can be found in a variety of Hsp90 associated TPR
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proteins (55). It has been established that Hsp90 is constantly sampling for available TPR
proteins and its function is determined by the TPR protein that binds. In which case,
immunophilins compete to bind to the MEEVD sequence in the extreme C-terminus of Hsp90
through their TPR (55). It is determined that the TPR domain interactions with Hsp90 are
required but are not enough for FKBP52 regulation of steroid hormone function (18, 56, 57).
Therefore, additional residues are required for the interaction’s affinity and specificity through
the Hsp90 MEEVD sequence (18, 56, 57).
1.5.2 FK2 Domain
We know that the FK2 domain is like the FK1 domain but lacks PPIase activity. The FK2
domain is required to maintain the overall size and structure of the FKBPs. Mutagenesis and
chimeric protein studies using FKBP51 and FKBP52 show that the FKBP52 FK2 domain is
critical for full receptor potentiation in response to TPR domain interactions (17, 18, 55). Due to
the lack of understanding about the FK2 domain, further studies need to be conducted to
determine the residues and regions critical for regulating receptor function.
1.5.3 FK Linker
The FK domain (FK linker) contains a 9-amino acid flexible hinge region that connects
the FK1 domain to the FK2 domain (18, 58). The FK linker has a consensus casein kinase II
(CKII) phosphorylation site (TEEED) that phosphorylates FKBP52 at position T143 which
hinders FKBP52 interaction with Hsp90 disrupts the regulation of steroid hormone receptor
function (18, 55). This is due to the destabilization and reorientation of the FK linker that results
in a allosteric rearrangement of the FK1 domain (18, 58–60).
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1.5.4 FK1 Domain
The FK1 domain is located in the first 138 amino acids in the N-terminus of FKBP52 and
along with the proline-rich loop, plays a critical role in forming an interaction site for receptor
potentiation. Due to in vitro studies, it has been established that FKBP52 potentiates hormonebinding affinity with AR, GR, and PR through interactions with the receptor LDB (18, 63–65).
Furthermore, the FK1 domain contains a functional PPIase catalytic pocket spanning from amino
acids 4-137, containing an overhanging proline-rich loop that is involved in receptor interactions
(18, 55, 61, 62). Increasing evidence suggest that it is the integrity of the PPIase pocket, rather
than its enzymatic activity, that is required for FKBP52 potentiation of AR activity (17, 18). This
proline-rich loop is critical for function, and likely represents an interaction surface that comes
into contact with the receptor hormone-binding domain within the AR-chaperone complex (17,
49, 63). The FKBP52 N-terminal FK506 binding domain (FK1) is required for receptor
regulation, while the proline-rich loop overhanging the PPIase catalytic pocket may serve as an
interaction surface (17, 48).
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(Sivils et. al. (2011) Current Opinion of Pharmacology. 11: 1-6)

Figure 1.5.4: Structure of FKBP52

The functional domains of FKBP52 are color-coded and have a brief description of their
function. The tetratricopeptide repeat domain (TPR; green) allows association with Hsp90
receptor complexes through interaction with the MEEVD motif at the C-terminal of Hsp90. The
FK2 (red) is like the FK1 domain but lacks PPIase activity. The FK linker (teal) connects the
FK2 (red) domain to the FK1 (blue) domain. The FK linker contains a casein kinase II
phosphorylation site that, when phosphorylated, abrogates FKBP52 function. The N-terminal
FK1 domain (blue) consists of a PPIase active site, this is where the immunosuppressive ligand
FK506 binds, and lastly, the proline-rich loop (yellow) that overhangs the PPIase pocket of the
FK1 domain is critical for receptor regulation (51).
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1.6 TARGETING FKBP52 FOR THE TREATMENT OF PROSTATE CANCER
As mentioned, FKBP52 has been identified as one of the tetratricopeptide repeats (TPR)containing peptidyl-prolyl cis/trans isomerase (PPIase) cochaperones that interact with Hsp90
and p23 in the mature SHR chaperone complex (66). FKBP52 has also emerged as an attractive
therapeutic target due to its specificity for small subsets of Hsp90 client proteins, which include
the androgen receptor (AR), glucocorticoid receptor (GR), and progesterone receptor (PR) (18).
The PPIase pockets of all FKBPs are known as “druggable targets” due to the
immunosuppressive drug FK506, also known as Tacrolimus, which is already FDA approved for
use in the clinic (18, 51). FK506 is a large molecule that binds to the PPIase pocket that, when
bound to FKBP12, forms a false interaction surface that binds with high affinity, the calcineurin
effect leads to immunosuppressive (48, 51, 67). Although FK506 targets FKBP PPIase pockets,
the immunosuppressive effects are due to FK506 binding to FKBP12. The fact that FKBP52 is
labeled as part of the immunophilin family is a misconception because FK506 binding to
FKBP52 does not cause immunosuppression but inhibits FKBP52-mediated potentiation of
steroid hormone receptor function and prostate cancer cell proliferation (51, 68). Molecules can
be easily docked in the FKBP52 PPIase pocket without causing immunosuppression. The
FKBP52 PPIase catalytic activity is not required for FKBP52 regulation of steroid hormone
receptor activity, nor are we interested in the activity. Our focus lies in the proline-rich loop that
overhangs the PPIase catalytic pocket within the FK1 domain. This domain is essential and
critical for function, and likely represents an interaction surface that contacts the receptor
hormone-binding domain within the AR-chaperone complex (17, 49, 63). Therefore, by docking
a drug, we can disrupt FKBP52 regulation of steroid hormone receptor function. FKBP52 has
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become a novel therapeutic target with the potential to treat CRPC and thereby filling a
significant unmet need in PCa treatment.
1.6.1 FKBP52 and b-Catenin Promote Androgen Receptor Function
Androgens bind to the hormone-binding pocket in the C-terminal ligand-binding domain
of AR. The ligand-binding domain consists of 12 α-helices; these helices are reorganized to an
agonist form for co-regulator binding to occur, known as the activation function 2 (AF2) (18,
69–72). As mentioned before, FKBP52 directly interacts with the ligand-binding domain (LBD)
within the Hsp90 heterocomplex. It has been proposed that Hsp90 brings the FKBP52 FK1
domain near the LBD for the interaction and regulation of receptor hormone binding (18, 48, 73).
As a result, studies have identified a surface region on the AR LBD that displays increased
dependence on FKBP52, and when mutated, this surface overlaps with the binding function 3
(BF3) (18, 48, 73). Little is known about the BF3 surface; it is a hydrophobic binding pocket on
the AR LBD and a docking site for short hydrophobic peptide motifs such as AR co-activators
(18, 73–78). Since the BF3 surface is near AF2, any small inhibitor docked in the BF3 surface
will disrupt the AF2 site preventing co-activator and co-regulator binding (18, 73). The AR BF3
surface may serve as an interaction surface for FKBP52 and a viable option for treating PCa.
There is a need to discover AR inhibitors that target alternative sites on AR, including
receptor-associated chaperones, cochaperones (FKBP52), co-activators (β-catenin), and AR
inhibitors for binding sites that are unknown (18, 79). The AR BF3 surface serves as an
optimistic regulatory surface for several co-regulators, including FKBP52 and β-catenin. Our
recent findings suggest that β-catenin regulates AR at a surface that overlaps with BF3 (49). We
published a paper showing that FKBP52 directly interacts with β-catenin to promote β-catenin
interaction with AR through the BF3 surface leading to a synergistic up-regulation of AR activity
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(49), in the absence of FKBP52, β-catenin does not regulate AR activity (49). FKBP52 is known
to regulate multiple distinct steps within the AR signaling pathway. Targeting FKBP52 and/ or
FKBP52 interactions with AR will disrupt β-catenin and other co-activators known to interact
and potentiate AR activity.
1.6.2 Targeting FKBP52/b-Catenin/Androgen Receptor Interactions
We know that FKBP52 binds directly to β-catenin and promotes β-catenin interaction
with AR through the BF3 surface (49). In the absence of FKBP52, β-catenin does not regulate
AR activity (49). The idea rests upon the fact that FKBP52 interacts with β-catenin to promote
interaction and regulate AR activity through the BF3 surface. Our lab has identified a small
molecule termed MJC13, which is thought to target the AR BF3 surface in the AR LBD to
inhibit dissociation of hormone-dependent AR/Hsp90/FKBP52 complex (18, 48). We have
demonstrated that MJC13 binds to the AR LBD in the presence of FKBP52, and freezes the AR
chaperone complex preventing AR translocation to the nucleus (48). We have also demonstrated
that MJC13 targets FKBP52 interactions with AR, blocking β-catenin interaction with AR (49,
80). Therefore, small molecules targeting the BF3 surface can inhibit FKBP52 mediated receptor
potentiation (48). In any case, MJC13 targets the putative FKBP52 regulatory site on the AR
hormone-binding domain rather than FKBP52 directly (18). Thus, we postulated that drugs that
target FKBP52 directly offer several advantages over MJC13, leading to a more potent and
effective drug. In congruence with this idea, the AR BF3 surface is not an ideal drug-binding site
considering that drugs that target the AR BF3 surface are attached to the AR LBD, leaving the
molecule exposed on the surface and easily replaced. Moreover, MJC13 does not target the
constitutively active AR missing the LBD, rendering it ineffective as a treatment for CRPC (66).
Targeting FKBP52 directly is a promising approach to regulate the activity of AR, GR, and PR,
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while abrogating FKBP52 proline-rich loop-mediated interactions between β-catenin and AR
(49, 80). Ultimately, direct targeting of FKBP52 with small molecules that bind tightly to that
PPIase pocket will lead to a more potent drug that will simultaneously hit multiple pathways
known to having a role in prostate cancer.
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(Guy, N.C. et. al. (2015) Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor Regulated Physiology and Disease. Current Molecular Pharmacology 109–125.)

Figure 1.6.5: Direct FKBP52 Targeting for the Treatment of Prostate Cancer

A guide of FKBP52 receptor interactions and therapeutic targeting strategies for the treatment of
CRPC. Solid lines are known and dashed are predicted interactions. FKBP52 interacts with βcatenin to promote AR activity, but in the absence of FKBP52, β-catenin does not potentiate AR
activity. We know that MJC13 binds to AR on the BF3 surface, in the presence of FKBP52
freezes the AR chaperone complex, preventing translocation to the nucleus. Therefore, targeting
FKBP52 directly will not only be inhibiting FKBP52 regulation of AR; but β-catenin regulation
of AR. We can hit multiple proteins simultaneously like GR, PR, NF-kB and disrupt chaperone
and cochaperone regulation of AR-mediated transcription (modified version 18).
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1.6.3 Targeting FKBP52 for the Direct Disruption of Proline-Rich Loop Interactions
The data suggest that the FKBP52 proline-rich loop overhanging the FKBP52 FK1
catalytic PPIase domain represents an interaction surface within the steroid hormone receptor
heterocomplex. Although PPIase activity is not essential for receptor function, the proline-rich
loop is critical for regulating AR activity. The proline-rich loop surface does not represent an
ideal hydrophobic drug-binding site, but the PPIase catalytic pocket does. Besides, available
evidence has shown that FKBP12 bound to FK506 could reorient proline-rich loop conformation
leading to the disruption of interactions. Therefore, confirming any molecules docked within this
PPIase pocket could reorientate the proline-rich loop.
1.7 ROLE OF GMC1
We have identified GMC1 as a molecule that directly targets FKBP52 cochaperone for
the treatment of PCa. We predict that GMC1 binds to the FKBP52 PPIase catalytic pocket in the
FK1 domain and reorients the proline-rich loop conformation leading to the disruption of
FKBP52 interactions within the steroid hormone receptor heterocomplex. We performed an in
silico structure-based drug design and screened the zinc database consisting of 3 million
commercially available compounds (66). Using docking stimulation, we identified a list of 40
molecules that were predicted to bind to FKBP52 with high affinity. Through functional
screening, we identified GMC1 as our initial hit molecule (66). GMC1 effectively blocks AR,
GR, and PR activity similarly, but has no effect on ER, blocks endogenous AR-mediated gene
expression, and inhibits the proliferation of various prostate cancer cell lines (66). Our
collaborator developed a co-solvent formulation of GMC1 that was injected intratumorally into
SCID mice and prevented tumor growth (81). We tested the effects of GMC1 in comparison to
MJC13 in CW22Rv1 cells; this cell line contains a truncated constitutively active AR variant
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(V7) co-expressed with full-length AR (66). Based on previous data, MJC13 most likely targets
the AR BF3 surface and is not expected to affect the truncated AR variant lacking the LBD. As
expected, MJC13 inhibited hormone-dependent PSA expression; but did not affect basal
hormone-independent PSA expression (66). In contrast, GMC1 inhibited both hormonedependent AR activity and basal hormone-independent PSA expression in this cell line (66). The
mechanism of GMC1 is currently unknown but is expected to target a variety of pathways in
CRPC. Ultimately this data will develop a more potent and soluble drug to treat CRPC (66).
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Guy, Naihsuan C., "Identification and Characterization of Small Molecules Targeting FKBP52 as a Novel Treatment for Prostate Cancer" (2016). Open Access Theses & Dissertations.
856. https://scholarworks.utep.edu/open_etd/856

Figure 1.7.6: GMC1 Inhibits AR and GR-dependent Gene Expression, Prostate Cancer Cell
Proliferation and Prostate Tumor Formation

GMC1 effects on prostate cancer cell lines. A. Docking of GMC1 in the FKBP52 PPIase pocket.
B. AR-mediated luciferase reporter assays were performed in 52KO MEFs in the presence or
absence of FKBP52 to assess AR-dependent expression. C. To assess AR- and GR-dependent
expression, luciferase reporter assays were performed in MDA-kb2 cells with GMC1
concentrations. D. Androgen-dependent PSA secretion was measured using LNCaP cells with a
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range of GMC1 concentrations. E. LNCaP cells were treated with GMC1 concentrations
followed by western blot to measure AR-dependent endogenous gene expression of FKBP51 and
PSA; the bottom graph represents densitometry of the blot above. F. The Cell Titer 96 NonRadioactive Cell Proliferation assay assessed GMC1 effects on hormone-dependent andindependent 22Rv1 cell proliferation. G. The Cell Titer 96 Non-Radioactive Cell Proliferation
assay was used to assess GMC1 effects on AR-independent cell proliferation in AR-negative
PC3 cells. H. GMC1 treatment started two weeks post-inoculation of CW22Rv1 tumor cells by
administering 5mg/kg of drug twice weekly for four consecutive weeks via intratumorally
injection in SCID mice. Data displays the weekly measurements of four control tumors vs. four
GMC1-treated tumors. The panel to the right shows representative tumors after removal from the
animals (66).
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1.8 POTENTIAL COMBINATORIAL THERAPIES IN CANCER
Over the last decade, β-blockers such as Propranolol and Carvedilol have emerged as
potential therapeutics alone or in combination with other drugs to treat patients with breast
cancer, prostate cancer, angiosarcoma, and ovarian cancer. Propranolol is a non-selective betaadrenoreceptor antagonist used to treat hypertension, myocardial infarction, anxiety, and tremors
(82, 83). Since Propranolol is a class II antiarrhythmic agent, it works by blocking beta-1 and
beta-2 adrenergic stimulation in the heart that is generally induced by epinephrine and
norepinephrine (84). Interestingly data has shown that Propranolol can sensitize prostate cancer
cells and prostate progression by inhibiting PAP activity of lipins that in turn inhibit autophagy
flux (82). Like Propranolol, Carvedilol is a non-selective alpha-1, and beta-adrenoreceptor
antagonist used to treat patients who have suffered from a heart attack, heart failure, or high
blood pressure (85–87). The sympathetic nervous system pathway is responsible for the initiation
and progression of cancer that involves inflammation, angiogenesis, and resistance to apoptosis;
Carvedilol works by mediating the sympathetic nervous system that induces the fight-or-flight
stress response (85). Carvedilol contains an overwhelming amount of antioxidants and antiinflammatory properties that help the sympathetic nervous system pathway (85). Taking
Carvedilol has shown to have anti-proliferation and anti-angiogenic effects, reduce cancer risk
by arresting cells at the G0/G1 phase, and reversing resistance to anti-cancer drugs by inhibiting
the P-glycoprotein, and in turn, this enhances the response to chemotherapy (85). Surprisingly
Carvedilol inhibits NF-kB and activator protein-1 transcription factors in human mononuclear
cells (85). This is compelling because FKBP52 is known to upregulate AR, GR, PR receptor
activity, and NF-kB, as shown in figure 1.5.5. Therefore, the targeting of FKBP52 with a β-

26

blocker can serve as a new therapeutic agent for the direct targeting of prostate cancer to prevent
drug resistance.
There is an unmet need for drug combination therapy with β-blockers and current antiandrogens. MDV3100 (Enzalutamide) is a second-generation androgen receptor antagonist
currently being used to treat prostate cancer. MDV3100 is an anti-androgen that competes for
binding to the androgen receptor with high affinity and, in turn, inhibits androgen binding (88).
MDV3100 reduces nuclear translocation efficacy, impairs DNA binding to androgen response
elements, and recruits co-activators (89). As previously mentioned, our lab developed a small
molecule known as MJC13 that targets the AR BF3 surface. Unlike MDV3100, MJC13 does not
displace androgens from the AR pocket but instead interacts with the BF3 surface and acts as an
AR surface-directed antagonist (80). MJC13 works by preventing hormone-induced AR/Hsp90
complex dissociation only in the presence of FKBP52 (18, 48). By doing this, MJC13 holds the
AR/Hsp90/FKBP52 complex in the cytoplasm reducing AR nuclear translocation, AR-dependent
gene expression, and androgen stimulated proliferation in prostate cancer cells (18, 48, 80).
Current therapies to treat prostate cancer rely on classic anti-androgens, and most tumors respond
to treatment initially but progress and become resistant to treatment, leaving classic antiandrogens such as MDV3100 useless. Research has shown that β-blockers reduce prostate
progression, reverse resistance to anti-cancer drugs, and in some cases, enhance the response to
chemotherapies that have stopped working. Therapies in combination with β-blockers have the
potential to prolong or extend the amount of time before a drug becomes resistant to current
therapies.
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1.9 DISSERTATION FOCUS AND HYPOTHESIS
We have pursued the therapeutic targeting of a novel cochaperone protein, known to be
critical for androgen receptor signaling and androgen receptor-dependent prostate development
in mice. The FKBP52 cochaperone is a highly promising therapeutic target for the disruption of
several essential mechanisms in PCa. FKBP52 is part of a family of well-defined druggable
targets with PPIase activity, and the catalytic site is an ideal hydrophobic drug-binding pocket.
Thus, our strategy aims to identify specific PPIase binding molecules that, when docked in the
pocket, reorient the proline-rich loop conformation leading to the disruption of FKBP52
interactions within the steroid hormone receptor heterocomplex.
Over several decades, studies have been conducted to determine the association between
β-blockers and cancer outcomes. Studies have demonstrated a strong correlation between taking
β-blockers, such as Propranolol and Carvedilol, in reducing tumor progression, metastasis, and
mortality in breast, ovarian, prostate, and melanoma patients. Beta-blockers, such as Propranolol
and Carvedilol, may serve as a supplement to existing anti-cancer therapeutics that are safe and
cost-effective.
Thus, we can hypothesize that 1) specific molecules targeting the FKBP52 PPIase pocket,
that can disrupt FKBP52 proline-rich loop conformation and interactions, will lead to effective
inhibition of AR, GR and PR signaling, PCa cell proliferation, and prostate tumor formation and
2) β-blockers, such as Propranolol and Carvedilol, may serve as a supplement to existing anticancer therapeutics to could extend the duration of current therapy.
1.10 DISSERTATION GOALS
This dissertation’s overall goal is to develop drugs that target FKBP52 interactions with
several proteins, including AR, known or suspected of having a role in PCa for the treatment of
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early-stage and castration-resistant prostate cancer. The exploration and development of drug
combination therapy with β-blockers can lead to a breakthrough in targeting drug resistance. To
assess these goals, we pursued the following specific aims:

1. Conduct a hit-to-lead optimization of GMC1 with the goal of increasing efficacy, reducing
toxicity, and ensuring bioavailability by performing functional screening of lead molecules using
SAR (structure-activity relationship) analysis.

2. Conduct a search for unique scaffolds of novel FKBP52 specific inhibitors by performing a
broader in silico screen against the FKBP52 PPIase pocket to generate a list of potential
FKBP52-specific hits for functional screening.

3. Assess drug combination therapies with anti-androgens and β-blockers in cellular models of
prostate cancer.

The drugs developed here will be first-in-class for the direct targeting of an AR
cochaperone to treat CRPC. Furthermore, the use of combination therapies with β-blockers is a
promising route in delaying the onset of drug resistance to current therapies. The studies herein
will lead to the development of novel CRPC therapeutic approaches through the direct or indirect
targeting of AR signaling.
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Chapter 2: Hit-to-Lead Optimization of GMC1 for Increased Potency and Metabolic
Stability
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2.1 RATIONALE
Based on our preliminary data on our initial hit molecule GMC1, we conducted a hit-tolead optimization with the goal of increasing efficacy, reducing toxicity, and ensuring
bioavailability of the compound. We performed this by 1) searching the Sigma-Aldrich® database
for lead molecules that contained 90% similarity to GMC1 in which included the same structure
as GMC1 but possessed different functional groups, 2) Vancouver Prostate Centre performed the
SAR analysis through the process of molecular docking, to identify lead molecules that are
predicted to bind to FKBP52 with high affinity and 3) through MAIA Biotech, we worked with
selected chemistry vendor WuXi Apptec that guided the synthesis of analogs of GMC1. The
androgen receptor (AR) belongs to the steroid hormone receptor family along with the
glucocorticoid receptor (GR), estrogen receptor (ER), progesterone receptor (PR), and
mineralocorticoid receptor (MR). Any molecules that inhibit ER activity are likely not targeting
FKBP52 because FKBP52 is not a functional regulator of ER. Besides AR, there are two
additional receptors regulated by FKBP52 that consist of GR and PR. Therefore, lead molecules
were tested in AR- and GR-mediated luciferase assays to assess drug effects on AR- and GRactivity using MDA-kb2 cell lines. In order to assess FKBP52 specificity, an AR-mediated
luciferase assay was conducted in mouse embryonic fibroblast derived from FKBP52 knockout
mice (52KO MEFs). Furthermore, lead molecules were tested in ER-mediated luciferase assays
to assess the effects on ER-regulated activity.
2.2 IN SILICO HIT-TO-LEAD OPTIMIZATION
GMC1 was initially found by a virtual screening platform that was used to conduct a
large scale in silico screening against the PPIase pocket for the identification of FKBP52 specific
hit compounds. Docking stimulation and scoring functions were used to generate a list of hit
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compounds that were predicted to bind to FKBP52 with high affinity. Novel GMC1 derivatives
were identified in the in silico hit-to-lead optimization at the Vancouver Prostate Centre site for
anti-AR activity to identify new lead drug molecules. The structure-based drug design and in
silico screening was done by searching millions of commercially available chemicals to identify
new lead drug molecules with novel chemistry that can be pursued for the composition of matter
patents.
Molecules GMC1-1 through GMC1-15 were not identified from the hit-to-lead
optimization; rather, purchase ordered through Sigma Aldrich®. We were simultaneously
identifying available modifications online through the advanced structure search provided by
Sigma Aldrich®. The search engine allows for our hit molecule GMC1 to be drawn on their
system and conducts a structure search for molecules that share a 90% structure similarity to
GMC1. Through this process, many leads arose, and we choose 15 molecules at random and
assayed them as described in the methods. These 15 molecules were then sent to our collaborator
to help with SAR analysis.
Based on the analogs’ data, an FKBP52 hit-to-lead optimization analog list was generated
of 159 molecules; GMC1 was used as a starting point for optimization by a hit-based similarity
search to develop more potent compounds and obtain preliminary SAR analysis. Instant JChem
5.9.0 (ChemAxon), a similarity search tool, was used. The concept is to import the zinc database
into the Instant JChem, and GMC1 was used as a query to identify analogs by structure
similarity. Analogs that share structure similarities will be docked into the PPIase binding site, in
which a docking score will predict their binding affinities. Through the process of molecular
docking, compounds with predicted high affinity binding were purchased and assayed; molecules
GMC1-16 though GMC1-31 are described in methods.
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2.3 MAIA BIOTECHNOLOGY
MAIA is an early-stage biotech company that focuses on developing targeted cancer
therapies. Their mission is to research, develop and deliver new medicines to improve and extend
the lives of individuals who have cancer (https://maiabiotec.com/). Through the secured
sponsored research agreement, MAIA acquired GMC1 to help in the process of SAR analysis to
further the hit-to-lead optimization. MAIA biotech (https://maiabiotec.com/) has provided the
needed chemistry support for lead molecules. We worked with a selected chemistry vendor
WuXi Apptec, to guide the synthesis of analogs of GMC1 with the goal of increasing efficacy,
reducing toxicity, and ensuring bioavailability of the compound. A total of 97 GMC1 modified
analogs were produced and were screened for inhibition of AR activity. We selected 5 GMC1
analogs that displayed significantly increased potency to send for ADME (absorption,
distribution, metabolism, and excretion), which was also performed through contract with WuXi
Apptec. Upon completion of ADME, two leads GMC-M-V28 and GMC-M-V27, were identified
to have the best PK/PD profiles and were then further characterized in mammalian cell-based
luciferase assays.
Table 2.3.1: Stages of Lead Analog Per MAIA
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2.4 MATERIAL AND METHODS
2.4.1 Cell Culture
MDA-kb2 cells were purchased from American Type Culture Collection (ATCC® CRL2713™). This cell line expresses firefly luciferase under the control of the MMTV promoter that
contains response elements for both AR and GR. The cell line was maintained in Hyclone™
Leibovitz’s L-15 media, containing 2.05mM L-glutamine (GE Healthcare Life Sciences) with
supplemental 10% fetal bovine serum (FBS, Corning) at 37ºC without CO2. Mouse embryonic
fibroblasts derived from FKBP52 knockout mice (52KO MEFs) were maintained in Hyclone™
Minimal Essential Media/ Earle’s Balanced Salt Solution (MEM/EBSS) containing 2mM Lglutamine (GE Healthcare Life Sciences) with supplemental 10% fetal bovine serum (FBS,
Corning) at 37ºC with 5% CO2. T47D-KBluc cells were purchased from American Type Culture
Collection (ATCC® CRL-2865™). This cell line was created using the T47D human breast
cancer cells that naturally express estrogen receptor alpha (ERα) and beta (ERβ); these cells
were transfected with pGL2.TATA.lnr.Luc.neo contains three estrogen response elements (ERE)
upstream of a Luc reporter gene (90). T47D-KBluc cells were used to screen for estrogenic
activity. The cell line was maintained in Hyclone™ RPMI 1640 media containing 25mM HEPES
and L-glutamine (GE Healthcare Life Sciences) with supplemental 10% fetal bovine serum
(FBS, Corning) at 37ºC with 5% CO2.
2.4.2 Mammalian Cell Based Luciferase Assay
To assess AR-dependent activity, MDA-kb2 cells were used for the Bright-Glo™
luciferase assay system (Promega) to screen compounds. AR agonist dihydrotestosterone (DHT)
was used to induce AR-mediated luciferase expression. The cells were plated at 2.0 x 104 cells
per well in a 96-well luminometer plate (Costar® 3610) in 100µL of Hyclone™ Leibovitz’s L-15
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media with supplemental 10% FBS and allowed to attach at 37°C without CO2. The next day, the
cells were washed three times with Hyclone™ Leibovitz’s L-15 media with supplemental 10%
charcoal-stripped FBS (CS-FBS; Innovative Research™), after the third wash, 100µL of media
containing 10% CS-FBS was added and allowed to incubate overnight at 37°C without CO2. The
following day, the 96-well plate was dosed with dimethyl sulfoxide (DMSO) + ethanol (EtOH)
(negative control), DMSO plus the agonist (DHT, at 200pM, which is the EC50 for the hormone
in the cell line; positive control) followed by a range of derivative concentrations, incubated for
30 minutes at 37°C without CO2. Once the incubation was complete, agonist (DHT 200pM) was
added to all wells containing the derivative, then incubated for 16-20 hours at 37°C without CO2.
The final EtOH and DMSO concentrations did not exceed 1%. The luciferase reporter assay was
performed by adding 100µL of reagent (Bright- Glo™) to each well than reading the plate
immediately. Relative light units (RLU) per well were determined using Synergy 2 Multi-Mode
micro-plate luminometer reader (BioTek) in which each concentration was assayed
independently with duplicate wells for every assay. The single high dose (25µM) AR-dependent
reporter assay followed the same procedure as above except only included one single high dose
and was done for a total of 97 derivatives.
To assess GR- dependent activity, MDA-kb2 cells were used for the Bright-Glo™
luciferase assay system (Promega) to screen compounds. GR agonist dexamethasone (DEX) was
used to induce GR-mediated luciferase expression. The cells were plated at 2.0 x 104 per well in
a 96-well luminometer plate (Costar® 3610) in 100µL of Hyclone™ Leibovitz’s L-15 media with
supplemental 10% FBS and allowed to attach at 37°C without CO2. The next day, the cells were
washed three times with Hyclone™ Leibovitz’s L-15 media with supplemental 10% CS-FBS;
after the third wash, 100µL of media containing 10% CS-FBS was added and allowed to
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incubate overnight at 37°C without CO2. The following day, the 96-well plate was dosed with
DMSO + EtOH (negative control), DMSO plus the agonist (DEX, at 50nM, the EC50 for the
hormone in the cell line; positive control) followed by a range of derivative concentrations,
incubated for 30 minutes at 37°C without CO2. Once the incubation was complete, agonist (DEX
50nM) was added to all wells containing the derivative, then incubated for 16-20 hours at 37°C
without CO2. The final EtOH and DMSO concentrations did not exceed 1%. The luciferase
reporter assay was performed by adding 100µL of reagent (Bright- Glo™) to each well than
reading the plate immediately. Relative light units (RLU) per well were determined using
Synergy 2 Multi-Mode micro-plate luminometer reader (BioTek) each concentration was
assayed independently with duplicate wells for every replicate assay.
2.4.3 Luciferase Assay and Transient Transfections
52KO MEFs were used to assess FKBP52-regulated AR-mediated luciferase activity.
The cells were plated at 3.0 x 105 per well in 6-well tissue culture treated plates (FALCON®) in
1.5mL of Hyclone™ MEM/EBSS media containing 2mM L-glutamine with supplemental 10%
FBS, allowed to attach at 37°C with 5% CO2. When the cells reached 80% confluency, a
transfection was conducted. The plasmids used were a β-galactosidase expression plasmid (pDS
371, 50ng per well; transfection control), a hormone-responsive firefly luciferase reporter (pDS
712, 400ng per well), a pCI-Neo mammalian expression vector expressing AR (pDS 923, 800ng
per well), an empty pCI-Neo mammalian expression vector (pDS 404, 800ng per well, negative
control) and an FKBP52 pCI-Neo mammalian expression plasmid (pDS 600, 800ng per well).
The plasmids were transfected using Lipofectamine® 2000 reagent (Invitrogen™, Thermo
Scientific) with a DNA to Lipofectamine® ratio of 1:3 in Hyclone™ MEM/EBSS media
containing 2mM L-glutamine without 10% FBS. Before adding transfection mixture, the 6-well
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plates were washed three times with Hyclone™ MEM/EBSS media containing 2mM Lglutamine without 10% FBS; after the third wash, 1mL of Hyclone™ MEM/EBSS media
containing 2mM L-glutamine without 10% FBS was added to each well followed by 500µL of
transfection mixture and allowed to incubate for 4-5 hours at 37°C with 5% CO2. After the
transfection incubation, the media was removed and replaced with 1.5mL of Hyclone™
MEM/EBSS media containing 2mM L-glutamine with supplemental 10% CS-FBS. After 24
hours of transfection, the media was removed and replaced with fresh 1.5mL of Hyclone™
MEM/EBSS media containing 2mM L-glutamine with supplemental 10% CS-FBS and treated
with a range of derivative concentrations (0, .001, .01, .05, .1, .5, 1, 10 and 100µM) for 30
minutes at 37°C with 5% CO2 followed by DHT and allowed to incubate for 16-18 hours at 37°C
with 5% CO2. The EC50 for the hormone in the mammalian expression vector 1nM and the
mammalian expression vector FKBP52 10pM. The final EtOH and DMSO did not exceed 0.1%
and 1%. After 16-18 hours, the cells were washed with Gibco® phosphate-buffered saline (PBS;
Life Technologies™) at room temperature followed by adding 150µL lysis buffer (10mL of MPER™ Mammalian Protein Extraction Reagent plus 100µL of Halt™ Protease Inhibitor SingleUse Cocktail EDTA-Free; Thermo Scientific™) to each well, placed on a shaker for 10 minutes
at room temperature. The cell lysates were collected by centrifugation at 15,000 rpm at 4°C for 20
minutes. The cell lysates were used to measure luciferase expression by using Luciferase Assay
System (Promega™). In an opaque 96-well plate, 40µL of cell lysate and 100µL of reagent
(Luciferase) were added to each well. The plate was read immediately to measure the relative
light units using Synergy 2 Multi-Mode micro-plate reader (BioTek). The β-galactosidase was
measured using Gal Screen® System (Applied Biosystems). In an opaque 96-well plate, 10µL of
cell lysate and 100µL of reagent (β-galactosidase) were added to each well, incubated for 2
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hours at room temperature. The plate was read to measure relative light units using Synergy 2
Multi-Mode micro-plate reader (BioTek). The reporter expression was normalized against
transfection efficiencies by dividing luciferase relative light units (RLU) by β-galactosidase
relative light units (RLU).
T47D-KBluc cells were used for the Bright-Glo™ luciferase assay system (Promega) to
screen derivatives for effects on ER-regulated activity. The cells were plated at 3.0 x 104 per well
in a 96-well luminometer plate (Costar® 3610) in 100µL of Hyclone™ RPMI 1640 media with
10% CS-FBS and allowed to incubate overnight at 37°C with 5% CO2. After 24 hours, the media
was refreshed with 100µL of Hyclone™ RPMI 1640 with 10% CS-FBS. The 96-well plate was
dosed with DMSO + EtOH (negative control), DMSO plus the agonist (estradiol, E2, at 10pM,
the EC50 for hormone in cell line; positive control) and a single high dose of 100µM derivative,
incubated for 30 minutes at 37°C with 5% CO2. Once the incubation was complete, agonist (E2,
10pM) was added to all wells containing derivative, incubated for 16-20 hours at 37°C with 5%
CO2. The final EtOH and DMSO concentrations did not exceed 1%. The luciferase reporter
assay was performed by adding 100µL of reagent (Bright- Glo™) to each well than reading the
plate immediately. Relative light units (RLU) per well were determined using Synergy 2 MultiMode micro-plate luminometer reader (BioTek); each concentration was assayed independently
with duplicate wells for every assay.
2.5 RESULTS
A total of 15 lead molecules were identified through an advanced structure search
provided by Sigma Aldrich®. The search engine provided by Sigma allows the GMC1 structure
(our initial hit molecule) to be drawn with tools provided by Sigma and conducts a structure
search through their database for structures that share a 90% similarity. Through this search
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engine, multiple leads were discovered in which we randomly chose molecules for purchase
(Table 2.5.2). All lead molecules purchased from Sigma Aldrich® were assessed for the ability to
inhibit AR-mediated luciferase activity in full dose curves to determine IC50 to assess drug
effects on AR activity (Figure 2.5.1). The data obtained were given to our collaborator, and this
helped in the process of SAR analysis. Based on the data, our collaborator produced a GMC1
analog list of 159 molecules in which 16 of those molecules were purchased from MolPort and
Vitas-M (Table 2.5.2). Each molecule was assessed for the ability to inhibit AR-mediated
luciferase activity (Figure 2.5.2). As stated before, GMC1 inhibits AR activity in the low µM
range. Unfortunately, the GMC1 analogs generated from Sigma Aldrich® did not inhibit AR
activity anywhere near the low µM range; in fact, either the molecule had no activity or was in
the mid µM range. As an alternative approach, we secured a sponsored research agreement with
MAIA Biotech in which they helped with the needed chemistry support for lead molecules. We
worked with the selected chemistry vendor WuXi Apptec to guide the synthesis of analogs of
GMC1 with the goal of increasing efficacy, reducing toxicity, and ensuring bioavailability of the
compound. This led to a modification’s library consisting of 97 molecules screened first at a
single high dose (25µM) for inhibition of AR activity in MDA-kb2 cell reporter assays. Any
analogs that inhibited AR activity by 75% or more were screened in full dose-response curves to
determine the IC50. From these data, we selected 5 GMC1 analogs that displayed significantly
increased potency to send for ADME, which was also performed through a contract with WuXi
Apptec (Figure 2.5.3). Out of the five molecules sent for ADME, there were two molecules,
GMC-M-V27 and GMC-M-V28, that showed high metabolic stability, intestinal permeability,
and solubility. Therefore, we decided to move forward with GMC-M-V27 and GMC-M-V28; we
wanted to assess the ability of the molecules to inhibit GR-dependent activity (GR is known to
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be regulated by FKBP52), test for FKBP52 specificity in the presence and absence of FKBP52
and assess the effects on ER-regulated activity (ER is not regulated by FKBP52) (Figure 2.5.4).
Thus, any molecules that inhibit GR but not ER activity are more likely to be specific for the
inhibition of FKBP52-regulated AR, GR, and PR activity. Although GMC-M-V28 inhibits GRregulated activity in the low µM range in MDA-kb2 cells, it did not show FKBP52 specificity in
the 52KO MEFs. However, it did show a preference for FKBP52 over vector. Therefore, we
wanted to see if GMC-M-V28 inhibited ER-regulated activity in T47D-KBluc cells, and
unfortunately, GMC-M-V28 did inhibit ER activity, meaning that we are not likely targeting
FKBP52. While GMC-M-V27 did not show FKBP52 specificity, it showed a predisposition
towards FKBP52, indicating that we could be targeting multiple FKBPs such as FKBP51, a
closely related family member of FKBP52 (Figure 2.5.5). We show that GMC-M-V27 does not
inhibit ER activity, indicating a preference towards AR activity. One can infer that we are
targeting FKBP52, a positive regulator of AR, GR, and PR specifically.
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Table 2.5.2: The Identification of FKBP52 Hit-to-Lead Optimization Analogs
Molecular
Weight

Compound
Library
Screen

IC50 (MDA-kb2)

C17H16N4O2S

340.4067

+

8.83E-06 ± 2.05E-06 (AR)

2-[(1-ETHYL-1H-BENZIMIDAZOL-2-YL)SULFANYL]-N'-[(E)-(3,4,5TRIMETHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE

C21H24N4O4S

428.51

+

1.394E-005 (AR)

R770574

N'-(3,4-DIMETHOXYBENZYLIDENE)-2-((1-ME-1H-BENZIMIDAZOL2-YL)THIO)ACETOHYDRAZIDE

C19H20N4O3S

384.46

+

No activity

GMC1- 3

R906352

N'-(3-BR-4-METHOXYBENZYLIDENE)-2-((1-ME-1HBENZIMIDAZOL-2-YL)THIO)ACETOHYDRAZIDE

C18H17BrN4O2S

433.33

+

1.798E-005 (AR)

GMC1- 4

R654914

N'-(4-ETHOXY-3-MEO-BENZYLIDENE)2-((1-ME-1HBENZIMIDAZOL-2-YL)THIO)ACETOHYDRAZIDE

C20H22N4O3S

398.49

+

No activity

GMC1- 5

R452912

2-[(1-ETHYL-1H-BENZIMIDAZOL-2-YL)SULFANYL]-N'-[(E)-(2,3,4TRIMETHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE

C21H24N4O4S

428.51

+

2.703E-005 (AR)

GMC1-6

R998931

N'-(2,4-DIMETHOXYBENZYLIDENE)-2-((1-ME-1H-BENZIMIDAZOL2-YL)THIO)ACETOHYDRAZIDE

C19H20N4O3S

384.46

+

1.735E-005 (AR)

GMC1- 7

R399957

2-(1H-BENZOIMIDAZOL-2-YLSULFANYL)-ACETIC ACID (2,4-DIMEO-BENZYLIDENE)-HYDRAZIDE

C18H18N4O3S

370.43

+

7.502E-005 (AR)

GMC1- 8

R400319

2(1H-BENZOIMIDAZOL-2-YLSULFANYL)ACETIC ACID (2,4,5-TRIMEO-BENZYLIDENE)HYDRAZIDE

C19H20N4O4S

400.46

+

No activity

GMC1-9

L102660

2-((1-ME-1H-BENZIMIDAZOL-2-YL)THIO)-N'-(2,4,5-TRI-MEOBENZYLIDENE)ACETOHYDRAZIDE

C20H22N4O4S

414.49

+

No activity

GMC1-10

R767042

2-((1-ME-1H-BENZIMIDAZOL-2-YL)THIO)-N'-(2,4,6-TRI-MEOBENZYLIDENE)ACETOHYDRAZIDE

C20H22N4O4S

414.49

+

No activity

GMC1-11

R400661

2-(1H-BENZOIMIDAZOL-2-YLSULFANYL)-ACETIC ACID (4PHENOXY-BENZYLIDENE)-HYDRAZIDE

C22H18N4O2S

402.48

+

No activity

GMC1-12

R654973

2-((1-METHYL-1H-BENZIMIDAZOL-2-YL)THIO)-N'-(4PROPOXYBENZYLIDENE)ACETOHYDRAZIDE

C20H22N4O2S

382.49

+

No activity

GMC1-13

R912034

2-(1H-BENZIMIDAZOL-2-YLTHIO)-N'-(4-ETHOXY-3METHOXYBENZYLIDENE)ACETOHYDRAZIDE

C19H20N4O3S

384.46

+

No activity

GMC1-14

R404756

2(1H-BENZOIMIDAZOL-2-YLSULFANYL)ACETIC ACID (3,4,5-TRIMEO-BENZYLIDENE)HYDRAZIDE

C19H20N4O4S

400.46

+

6.854E-005 (AR)

GMC1-15

R401218

4-((E)-{[(1H-BENZIMIDAZOL-2YLSULFANYL)ACETYL]HYDRAZONO}METHYL)-2,6DIMETHOXYPHENYL ACETATE

C20H20N4O5S

428.47

+

No activity

GMC1-16

Vitas-M
STK090298

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-(4propoxyphenyl)methylidene]acetohydrazide

C19H20N4O2S

368.46

+

No activity

GMC1-17

Vitas-M
STK070344

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-(3-bromo-4methoxyphenyl)methylidene]acetohydrazide

C17H15BrN4O2S

419.30

+

No activity

GMC1-18

Vitas-M
STK081146

4-[(1E)-{[2-(1H-1,3-benzodiazol-2-ylsulfanyl)acetamido]imino}methyl]2-methoxyphenyl acetate

C19H18N4O4S

398.44

+

No activity

GMC1-19

Vitas-M
STK036156

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-1-(4methoxyphenyl)ethylidene]acetohydrazide

C18H18N4O2S

354.43

+

2.302E-005 (AR)

GMC1-20

Vitas-M
STK003312

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-(4ethoxyphenyl)methylidene]acetohydrazide

C18H18N4O2S

354.43

+

No activity

GMC1-21

Vitas-M
STL046260

2-[({N'-[(1E)-(4-methoxy-3oxidophenyl)methylidene]hydrazinecarbonyl}methyl)sulfanyl]-1H-1,3benzodiazol-3-ium

C17H16N4O3S

356.40

+

No activity

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(3,4dimethoxyphenyl)methylidene]acetohydrazide

Stored

Product Number

Systemic Name (IUPAC)

Empirical Formula

GMC1

R404802

2-(1H-BENZOIMIDAZOL-2-YLSULFANYL)-ACETIC ACID (4METHOXY-BENZYLIDENE)-HYDRAZIDE

GMC1- 1

R454850

GMC1- 2

MolPort-039-129GMC1-22
774

Structure

C18H18N4O3S

370.43

+

7.903E-005 (AR)

GMC1-23

Vitas-M
STK958764

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-1-(4methoxyphenyl)ethylidene]propanehydrazide

C19H20N4O2S

368.46

+

2.108E-005 (AR)

GMC1-24

Vitas-M
STK030497

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(1E)-(2,3,4trimethoxyphenyl)methylidene]acetohydrazide

C19H20N4O4S

400.45

+

No activity

GMC1-25

Vitas-M
STK024906

2-{4-[(1E)-{[2-(1H-1,3-benzodiazol-2ylsulfanyl)acetamido]imino}methyl]-2-methoxyphenoxy}acetamide

C19H19N5O4S

413.45

+

No activity

GMC1-26

MCULE
2952575434

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[1-(3,4dimethoxyphenyl)ethylidene]acetohydrazide

C19H20N4O3S

384.45

+

No activity

GMC1-27

MCULE
9503467070

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[1-(4methoxyphenyl)ethylidene]propanehydrazide

C19H20N4O2S

368.46

+

4.007E-005 (AR)

GMC1-28

MCULE
1535231050

2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(2,3,4trimethoxyphenyl)methylidene]acetohydrazide

C19H20N4O4S

400.45

+

7.406E-005 (AR)

GMC1-29

MCULE
5129764921

2-[4-({[2-(1H-1,3-benzodiazol-2-ylsulfanyl)acetamido]imino}methyl)-2methoxyphenoxy]acetamide

C19H19N5O4S

413.45

+

No activity

GMC1-30

MCULE
3723959025

4-({[2-(1H-1,3-benzodiazol-2-ylsulfanyl)acetamido]imino}methyl)-2methoxyphenyl acetate

C19H18N4O4S

398.44

+

No activity

GMC1-31

MCULE
3204164127

4-({[2-(1H-1,3-benzodiazol-2-ylsulfanyl)acetamido]imino}methyl)-2,6dimethoxyphenyl acetat

C20H20N4O5S

428.46

+

No activity

The table displays the systemic name, empirical formula, structure, molecular weight, and the
IC50 of all inhibitory curves for all derivatives that have been tested in MDA-kb2 cell lines. The
first 15 lead molecules were obtained by the advanced structure search database by Sigma
Aldrich® that share 90% structure similarity to GMC1. The rest of the GMC1-16 through
GMC1-31 were obtained from a list of 159 structures generated from our collaborator through
SAR analysis.
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Figure 2.5.1: AR-Mediated Luciferase Reporter Assays from Sigma AldrichÒ Database

MDA-kb2 cells were treated in a range of derivative concentrations, incubated for 30 minutes
then treated with DHT (200pM) to test for AR-dependent activity. A. GMC1-1 IC50 (µM) of
1.394E-005. B. GMC1-2 no activity. C. GMC1-3 IC50 (µM) of 1.798E-005. D. GMC1-4 no
activity E. GMC1-5 IC50 (µM) of 2.703E-005. F. GMC1-6 IC50 (µM) of 1.735E-005. G. GMC1-7
IC50 (µM) of 7.502E-005. H. GMC1-8 no activity. I. GMC1-9 no activity. J. GMC1-10 no
activity. K. GMC1-11 no activity. L. GMC1-12 no activity. M. GMC1-13 no activity. N. GMC114 IC50 (µM) of 6.854E-005. O. GMC1-15 no activity.
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Figure 2.5.2: AR-Mediated Luciferase Reporter Assays from SAR Analysis

MDA-kb2 cells were treated in a range of derivative concentrations, incubated for 30 minutes
then treated with DHT (200pM) to test for AR-dependent activity. A. GMC1-16 no activity. B.
GMC1-17 no activity. C. GMC1-18 no activity. D. GMC1-19 IC50 (µM) of 2.302E-005. E.
GMC1-20 no activity. F. GMC1-21 no activity. G. GMC1-22 IC50 (µM) of 7.903E-005. H.
GMC1-23 IC50 (µM) of 2.108E-005. I. GMC1-24 no activity. J. GMC1-25 no activity. K.
GMC1-26 no activity. L. GMC1-27 IC50 of 4.007E-005. M. GMC1-28 IC50 (µM) of 7.406E-005.
N. GMC1-29 no activity. O. GMC1-30 no activity. P. GMC1-31 no activity.
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Figure 2.5.3: Structure-Activity Relationship (SAR) Analysis of GMC1 Derivatives from WuXi
AppTec

SAR aided in the synthesis of analogs of GMC1, generating an initial modification library
consisting of 97 molecules. Molecules were assessed for the ability to inhibit AR-mediated
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luciferase expression at a single high concentration (25µM) in MDA-kb2 cells. Molecules that
showed inhibition at 25µM were assessed in full dose-response curves to determine the IC50.
MDA-kb2 cells were treated with 200pM DHT with a range of derivative concentrations. Any
molecule in the low µM range moved to the next step in screening for ADME properties to
ensure that derivatives contained suitable properties for formulation and oral dosing.
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Figure 2.5.4: GMC-M-V28 Inhibits FKBP52 Specific AR, GR and ER- Mediated Activity

GMC-M-V28 effects on a variety of cell lines. A. MDA-kb2 cells were treated in a range of
GMC-M-V28 concentrations (0, .01, .1, 1, 10, 25, 50, and 100µM) incubated for 30 minutes,
then treated with dexamethasone (50nM) for 16 to 20 hours to test for GR-dependent activity.
The graph represents an average of three independent experiments. B. 52KO MEF cells were
used to test for FKBP52 specificity in the presence and absence of FKBP52. The cells were
treated in a range of GMC-M-V28 concentrations (0, .001, .01, .05, .1, .5, 1, 10, and 100µM),
incubated for 30 minutes then treated with 10pM DHT and 1nM DHT to test for FKBP52
specific AR-mediated activity. C. T47D-KBluc cells were used to assess the effects of GMC-MV28 on ER-regulated activity. The cells were treated with a single high dose of 100µM GMC-MV28, incubated for 30 minutes, then dosed with 10pM estradiol (E2) and incubated for 16-20
hours.
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Figure 2.5.5: GMC-M-V27 Inhibits FKBP52 Specific AR-Mediated Activity

GMC-M-V27 inhibits AR-mediated activity. A. 52KO MEF cells were used to test for FKBP52
specificity in the presence and absence of FKBP52. The cells were treated in a range of GMCM-V27 concentrations (0, .001, .01, .05, .1, .5, 1, 10 and 100µM), incubated for 30 minutes then
treated with 10pM DHT and 1nM DHT to test for FKBP52 specific AR-mediated activity. B.
T47D-KBluc cells were used to assess the effects of GMC-M-V27 on ER-regulated activity. The
cells were treated with a single high dose of 100µM GMC-M-V27, incubated for 30 minutes,
then dosed with 10pM estradiol (E2) and incubated for 16-20 hours.
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2.6 DISCUSSION
We have identified a hit molecule (GMC1) that inhibits FKBP52-mediated AR, GR, and
PR activity, AR-dependent gene expression in prostate cancer cells, AR-dependent proliferation
of prostate cancer cells, and tumor growth in murine models (66). A hit-to-lead optimization was
conducted by a chemistry vendor (WuXi Apptec) through MAIA biotech to guide the synthesis
of analogs of GMC1 to increase efficacy, reduce toxicity, and ensuring bioavailability of the
compound. MAIA biotech provided the chemistry support needed for lead molecules in which
GMC-M-V28 and GMC-M-V27 were discovered. Although GMC-M-V28 serves as an
unfavorable lead molecule, it does provide insight into the molecules / functional groups we
should stay away from. We show that GMC-M-V28 inhibits AR- and GR-regulated activity and
shows preference to FKBP52 specificity but unfortunately inhibits ER-regulated activity,
meaning that we are targeting all steroid hormone receptors because FKBP52 is not a functional
regulator of ER. GMC-M-V27 serves as a reliable lead molecule in that it inhibits AR-regulated
activity, shows preference to FKBP52 specificity, and does not inhibit ER-regulated activity.
Since GMC-M-V27 does not inhibit ER activity, it shows a preference for AR activity. While we
have not tested it for inhibition of GR and PR activity, two additional receptors known to be
regulated by FKBP52, it does show preference for FKBP52-regulated AR activity in the 52KO
MEF assays. GMC-M-V27 inhibits AR activity in the absence of FKBP52 but at high,
physiologically irrelevant hormone concentrations. Besides, showing FKBP52-specific inhibition
would be difficult for direct FKBP52 targeting drugs as we are targeting a highly conserved
pocket among the FKBP family of proteins, and it is likely that we are targeting a variety of
FKBPs. The family as a whole is druggable, as evidenced by the clinically available Tacrolimus.
In addition, targeting the family may be therapeutically desirable as FKBP51, for example, has
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been shown to positively regulate AR activity in some prostate cancer cell models. The ultimate
conclusion is that we have identified a GMC1 analog that displays increased potency and a better
metabolic profile that can now be used as the starting point for further SAR.
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Chapter 3: In Silico Screening Against the FKBP52 PPIase Pocket for Novel FKBP52Specific Inhibitors
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3.1 RATIONALE
While we have identified and are optimizing GMC1 for the direct targeting of FKBP52
for the treatment of prostate cancer, we also aimed to identify unique scaffolds that can be
pursued independently of GMC1. First, GMC1 has been challenging to work with and likely has
some stability problems. Second, given that many drugs fail in development, the more unique
scaffolds we can identify and pursue, the better. Given the above, we decided to perform a much
broader in silico screen as compared to the screen that identified GMC1. Thus, our collaborator
at Vancouver Prostate Centre, Dr. Artem Cherkasov, conducted an in silico screen against the
FKBP52 PPIase pocket that identified novel FKBP52-specific hits that targeted the FKBP52
PPIase pocket. The novel FKBP52-specific hits demonstrated inhibition of AR, GR, and PRmediated luciferase expression and showed FKBP52 specificity in various FKBP52 knockout
cell lines. Previously, the only cellular model for assessing drug effects in the presence or
absence of FKBP52 were mouse embryonic fibroblast derived from 52KO mice. With the
CRISPR/CAS9, we now have the ability to generate 52KO in human cell lines, which represent a
more relevant system. Prostate cancer cells are highly dependent on AR for proliferation, and AR
is highly reliant on FKBP52 for function. Thus, deletion of FKBP52 in most prostate cancer cells
leads to a lack of proliferation. While this is a strong validation of FKBP52 as a target for
inhibiting AR, it is difficult to use these cell lines to assess drug effects. Given this, we decided
to establish a 52KO human cellular model using Hela cells, a cell line that has been widely used
to study steroid hormone receptor signaling.
Furthermore, the 51-KDa FK506-binding protein (FKBP51) is a member of the steroid
chaperone complex. Studies have shown that FKBP51 is part of a pre-ligand AR chaperone
complex, and overexpression of FKBP51 increases AR transcriptional activity (87). Another
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clinically significant biomarker is the prostate-specific antigen (PSA). PSA is regulated by the
androgen receptor at the transcriptional level (88). Therefore, specific molecules targeting the
FKBP52 PPIase pocket will disrupt FKBP52 proline-rich loop interactions leading to the
effective inhibition of multiple cellular targets, including β-catenin regulation of AR, FKBP52,
and possibly FKBP51 regulation of AR, GR, and PR. Any hit molecules discovered represent an
entirely new structure that can be pursued and patented independently of GMC1.
3.2 IN SILICO SCREEN FOR NOVEL SCAFFOLDS THAT CAN BE PURSUED INDEPENDENTLY OF
GMC1
Dr. Artem Cherkasov at the Vancouver Prostate Centre conducted a large-scale in silico
screen against the FKBP52 PPIase pocket. The virtual screening pipeline and in silico library
identified small molecules targeting the FKBP52 PPIase pocket. The ZINC15 library identified
132 million compounds that were downloaded and filtered with OpenEye software. The
18,000,000 molecules were then separated by molecular weight between 350 and 500 Daltons,
chiral centers less than or equal to 2, a charge of 0, logP between 2 and 5, and elements H, C, N,
O, F, P, S, CI, Br and I were selected for Glide-SP docking evaluation. After docking, 100,000
Glide-docked compounds were then ranked using a pharmacophore model and a CoMSIA 3DQSAR model. Visual selection identified 107 novel FKBP52-specific hits for functional
screening that target the FKBP52 PPIase pocket (Dr. Artem Cherkasov).
Table 3.2.1: In Silico Screen
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3.3 GENERATION OF 52KO MODELS IN HUMAN CELLS FOR RELEVANT ASSESSMENTS OF 52
SPECIFICITY
The HeLa FKBP4 knockout cell pool was purchased from Synthego, a company that uses
CRISPR-Cas9 to generate edited cell pools. The cell pool contains a heterogeneous mix of
unedited cells. A CRISPR design tool is used to produce multiple guide RNAs to target the gene
of interest; the guide RNAs have an early exon or target a standard transcript
(https://www.synthego.com). The guided RNAs are synthesized through an automated synthetic
process that produces chemically modified single guide RNAs (sgRNA)
(https://www.synthego.com). Electroporation is the primary transfection method, a process that
introduces DNA/chromosomes into cells using pulse electricity by opening the pores. Guide
RNAs are intricate with SpCas9 to form ribonucleoprotein (RNP) that will be transiently
expressed to create a genome change containing an edited population of a gene knockout
(https://www.synthego.com). Verification of knockout sequences is achieved via PCR-amplify
and sequencing the amplicons via Sanger sequencing. The data is analyzed through the Inference
CRISPR Edits (ICE) software tool that calculates edits’ frequency resulting in a knockout. The
ICE report for the FKBP4 knockout cell pool detailed guide RNA sequence was
‘UCCCAGGUCAUCAAGAGAGA,’ and 48-hour post-transfection editing efficiency was 97%,
the editing efficiency after expansion was 97% with 95.4% viability
(https://www.synthego.com).
3.4 STATISTICAL ANALYSIS
The graphs represent an average of three independent experiments. GraphPad Prism 8.4.2
was used to make all graphs. The immunoblot is a representative blot of four independent
experiments. ImageJ facilitated in the densitometry data; the loading control was used to

53

normalize target protein expression. Data was analyzed by One-Way ANOVA and Bonferroni’s
multiple comparisons test; control was compared to each treatment. The analysis shows a
significant difference between treatment and control with a P-value of

****

P≤ 0.0001. The final

EtOH and DMSO concentrations did not exceed 0.1% and 1%.
3.5 MATERIAL AND METHODS
3.5.1 Cell Culture
Refer to previous chapter 2 and section 2.4 for maintenance on MDA-kb2, 52KO MEFs,
and T47D-KBluc cell lines. The WT HeLa cells were purchased from Synthego, a human cervix
adenocarcinoma epithelial cell line. WT HeLa cells were maintained in Hyclone™ Minimal
Essential Media/ Earle’s Balanced Salt Solution (MEM/EBSS) containing 2mM L-glutamine
(GE Healthcare Life Sciences) with supplemental 10% FBS at 37ºC with 5% CO2. HeLa 52KO
(FKBP4) cell line was purchased from Synthego and maintained in Hyclone™ Minimal
Essential Media/ Earle’s Balanced Salt Solution (MEM/EBSS) containing 2mM L-glutamine
(GE Healthcare Life Sciences) with supplemental 10% FBS at 37ºC with 5% CO2. The 22RV1
52KO cell line was purchased from Synthego and maintained in Hyclone™ RPMI 1640 media
containing 25mM HEPES and L-glutamine (GE Healthcare Life Sciences) with supplemental
10% FBS at 37ºC with 5% CO2. The WT 22Rv1 cells were purchased from American Type
Culture Collection (ATCC® CRL-2505™). 22Rv1 is a human prostate carcinoma epithelial cell
line derived from a xenograft serially propagated in mice after castration-induced regression and
relapse of parental androgen-dependent CWR22 xenograft (91). The cell line expresses both
androgen-responsive and androgen-insensitive characteristics. 22Rv1 cells were maintained in
Hyclone™ RPMI 1640 media containing 25mM HEPES and L-glutamine (GE Healthcare Life
Sciences), supplemented with Hyclone™ 1% sodium pyruvate (Thermo Fisher), Hyclone™1%
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MEM-nonessential amino acids (MEM-NEAA, Thermo Fisher) and 10% FBS at 37ºC with 5%
CO2. LNCaP cells were purchased from American Type Culture Collection (ATCC® CRL1740™). This cell line was derived from a metastatic site of prostate carcinoma. LNCaP cells
were maintained in Hyclone™ RPMI 1640 media containing 25mM HEPES and L-glutamine
(GE Healthcare Life Sciences) with supplemental 10% FBS at 37ºC with 5% CO2. VCaP cells
were purchased from American Type Culture Collection (ATCC® CRL-2876™) and are derived
from vertebral bone metastasis from a patient with prostate cancer. VCaP cells were maintained
in ATCC® DMEM containing high glucose with L-glutamine (ATCC® 30-2002™) with
supplemental 10% FBS at 37ºC with 5% CO2. C4-2 cell lines were purchased from American
Type Culture Collection (ATCC® CRL-3314™) and were isolated from a human prostate
LNCaP cell line from a xenograft tumor of a castrated mouse. C4-2 cells were maintained in
Hyclone™ RPMI 1640 media containing 25mM HEPES and L-glutamine (GE Healthcare Life
Sciences) with supplemental 10% FBS at 37ºC with 5% CO2.
3.5.2 Mammalian Cell Based Luciferase Assay
Refer to previous chapter 2 and section 2.4 for AR-dependent activity, GR-dependent
activity in MDA-kb2 cells, FKBP52-regulated AR-mediated luciferase assay in 52KO MEFs,
and ER-regulated activity in T47D-KBluc cells (media was substituted for Hyclone™ RPMI
1640 media containing L-glutamine with no phenol red and supplemented with 10% CS-FBS.
3.5.3 Luciferase Assay and Transient Transfection
WT HeLa cells were used to assess PR-dependent activity. PR agonist P4 was used to
induce PR-mediated luciferase activity. The cells were plated at 3.0 x 105 per well in 6-well
tissue culture treated plates (FALCON®) in 1.5mL of respective standard growth media
described in section 3.5.1, allowed to attach at 37°C with 5% CO2. The cells were transiently
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transfected with a β-galactosidase expression plasmid (pDS 371, 50ng per well; transfection
control), a mammalian expression MMTV-Luc-Reporter (pDS 372, 400ng per well), and pCINeo mammalian expression vector expressing PR-B (pDS 803, 800ng per well). Plasmids were
transfected using Lipofectamine® 2000 reagent with a DNA to Lipofectamine® ratio of 1:3 in
respective standard growth media without FBS. Before adding the transfection mixture, the 6well plates were washed three times with respective standard growth media without FBS. After
the third wash, 1mL of respective standard growth media without FBS was added to each well,
followed by 500µL of transfection mixture and allowed to incubate for 4-5 hours at 37°C with 5%
CO2. After the transfection incubation, the media was removed and replaced with 1.5mL of
respective standard growth media with supplemental 10% CS-FBS. After 24 hours, the media
was removed and replaced with fresh 1.5mL of respective standard growth media with
supplemental 10% CS-FBS and treated with derivative concentrations (0, .01, .1, 1, 10, 25, 50,
and 100µM) for 30 minutes at 37°C with 5% CO2 followed by P4 (4nM, the EC50 for the hormone
in the cell line) and allowed to incubate for 16 to 18 hours at 37°C with 5% CO2. After 16-18
hours, the cells were washed with PBS at room temperature, followed by adding 150µL lysis
buffer (MPER/Halt) to each well, placed on a shaker for 10 minutes at room temperature. The
cell lysates were collected by centrifugation at 15,000 rpm at 4°C for 20 minutes. The lysates
were used to measure luciferase expression by using Luciferase Assay System (Promega™). In
an opaque 96-well plate, 40µL of cell lysate and 100µL of reagent (Luciferase) were added to
each well. The plate was read immediately to measure the relative light units using Synergy 2
Multi-Mode micro-plate reader (BioTek). The β-galactosidase was measured using Gal Screen®
System (Applied Biosystems). In an opaque 96-well plate, 10µL of cell lysate and 100µL of
reagent (β-galactosidase) was added to each well, then placed aside to incubate for 2 hours at
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room temperature in the dark. After 2 hours, the plate was read to measure relative light units
using Synergy 2 Multi-Mode micro-plate reader (BioTek). The reporter expression was
normalized against transfection efficiencies by dividing luciferase relative light units (RLU) by
β-galactosidase relative light units (RLU).
HeLa 52KO and 22RV1 52KO cells were used to assess FKBP52-regulated AR-mediated
luciferase activity. The cells were plated at 3.5 x 105 (HeLa 52KO) and 9.0 x 105 (22RV1 52KO)
per well in 6-well tissue culture treated plates (FALCON®) in 1.5mL of respective standard
growth media as described in section 3.5.1 and allowed to attach at 37°C with 5% CO2. Once cells
reached 80% confluency, a transfection was conducted. The plasmids used for the experiment
were the following: a β-galactosidase expression plasmid (pDS 371, 50ng per well; transfection
control), a hormone-responsive firefly luciferase reporter (pDS 712, 400ng per well), a pCI-Neo
mammalian expression vector expressing AR (pDS 923, 800ng per well), an empty pCI-Neo
mammalian expression vector (pDS 404, 800ng per well, negative control) and an FKBP52 pCINeo mammalian expression plasmid (pDS 600, 800ng per well). The plasmids were transfected
using Lipofectamine® 2000 reagent with a DNA to Lipofectamine® ratio of 1:3 in respective
standard growth media without FBS. Before adding transfection mixture, the 6-well plates were
washed three times with respective standard growth media without FBS. After the third wash,
1mL of respective standard growth media without FBS was added to each well, followed by
500µL of transfection mixture and allowed to incubate for 4-5 hours at 37°C with 5% CO2. After
incubation, the media was removed and replaced with 1.5mL of respective growth media
modified with 10% CS-FBS and treated with derivative concentrations (0, .001, .01, .05, .1, .5, 1,
10, and 100µM) for 30 minutes (HeLa 52KO) and one hour (22RV1 52KO) at 37°C with 5% CO2
followed by DHT and allowed to incubate for 16-18 hours at 37°C with 5% CO2. The EC50 for the
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hormone in the mammalian expression vector is 4nM, and the mammalian expression vector
FKBP52 100pM. After 16-18 hours, the cells were washed with PBS at room temperature,
followed by adding 150µL lysis buffer (MPER/Halt) to each well, placed on a shaker for 10
minutes at room temperature. The cell lysates were collected by centrifugation at 15,000 rpm at
4°C for 20 minutes. The lysates were used to measure luciferase expression by using Luciferase
assay system (Promega). In an opaque 96-well plate, 40µL of cell lysate and 100µL of reagent
(Luciferase) were added to each well. The plate was read immediately to measure the relative
light units using Synergy 2 Multi-Mode micro-plate reader (BioTek). The β-galactosidase was
measured using Gal Screen® System (Applied Biosystems). In an opaque 96-well plate, 10µL of
cell lysate and 100µL of reagent (β-galactosidase) were added to each well, incubated for 2
hours at room temperature. The plate was read to measure relative light units using Synergy 2
Multi-Mode micro-plate reader (BioTek). The reporter expression was normalized against
transfection efficiencies by dividing luciferase relative light units (RLU) by β-galactosidase
relative light units (RLU).
3.5.4 Western Blot
WT 22Rv1 cells were plated at 3.5 x105 per well in 12-well tissue culture treated plates
(FALCON®) in 1mL of respective standard growth media described in 3.5.1, allowed to incubate
at 37ºC with 5% CO2. After 24 hours, cells were washed three times with PBS. After the third
wash, 1mL of respective growth media modified with 10% CS-FBS was added to each well.
After 24 hours media was replenished with 1mL respective growth media modified with 10%
CS-FBS and treated with PC257 concentrations (0, .1, .5, 1, 10, 25, 50, 75, and 100µM),
incubated for one hour followed by DHT (1nM FKBP51 and 300pM PSA). After 24 hours, the
cells were washed with PBS at room temperature, followed by adding 150µL lysis buffer
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(MPER/Halt) to each well, placed on a shaker for 10 minutes at room temperature. The lysates
were collected by centrifugation at 15,000 rpm at 4°C for 20 minutes. In order to determine
protein concentration in each sample, Pierce™ Coomassie (Bradford) Protein Assay Kit (Thermo
Scientific) was used. Proteins (25ug lysate PSA, 30ug lysate FKBP51, and 20ug lysate GAPDH)
were loaded onto Invitrogen Bolt™ 4-12% Bis-Tris Plus Precast gels (Thermo Fisher Scientific).
Proteins were separated by electrophoresis, transferred to Immobilon® -P Polyvinylidene
Difluoride Membrane (Millipore Sigma). Membranes were washed for 5 minutes in 1xTrisBuffered Saline containing 0.1% Tween 20 (1xTBST) then blocked for 1-hour an appropriate
blocking buffer. PSA 5% w/v bovine serum albumin (BSA; Sigma) / 1xTris-Buffered Saline
containing 0.1% Tween 20 (1xTBST) and 5% nonfat dry milk in 1xTris-Buffered Saline
(1xTBS) for GAPDH and FKBP51. Primary antibodies included: rabbit monoclonal antiPSA/KLK3 D6B1 XP® (1:1000; Cell Signaling), mouse monoclonal anti-FKBP51 Hi51B
(1:5000; developed in the lab of Dr. David Smith), and mouse monoclonal anti-GAPDH (1:3000;
loading control; Santa Cruz Biotechnology). Primary antibodies were diluted an appropriate
blocking buffer and allowed to incubate with appropriate membranes overnight at 4°C. The next
morning membranes were washed 5 times with 1xTBST for 5 minutes on a shaker at room
temperature. Secondary antibodies consisted of alkaline-phosphatase conjugated goat anti-mouse
IgG (1:5000; Southern Biotech) and alkaline-phosphatase conjugated goat anti-rabbit IgG
(1:5000; Southern Biotech), diluted an appropriate blocking buffer and allowed to incubate with
membrane for 1-hour on a shaker at room temperature. The membranes were washed 5 times
with 1xTBST for 5 minutes on a shaker at room temperature. Membranes were developed with
Immuno-Star™ AP substrate (BioRad) and exposed on CL-X Posure™ film (Thermo Scientific)
for detection of antibodies.
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LNCaP and C4-2 cells were plated at a density of 2.5 x 105 and 3.0x105 per well in 12well tissue culture treated plates (FALCON®) in 1mL of respective standard growth media
described 3.5.1, allowed to incubate at 37ºC with 5% CO2. After 24 hours, cells were washed
three times with PBS. After the third wash, 1mL of respective growth media modified with 10%
CS-FBS was added to each well. After 24 hours media was replenished with 1mL respective
growth media modified with 10% CS-FBS and treated with PC257 concentrations (0, .1, .5, 1,
10, 25, 50, 75, and 100µM), incubated for 1-hour followed by DHT (LNCaP 50nM and C4-2
25nM). After 24 hours, the cells were washed with PBS at room temperature, followed by adding
150µL lysis buffer (MPER/Halt) to each well, placed on a shaker for 10 minutes at room
temperature. The cell lysates were collected by centrifugation at 15,000 rpm at 4°C for 20
minutes. In order to determine protein concentration in each sample, Pierce™ Coomassie
(Bradford) Protein Assay Kit (Thermo Scientific) was used. Proteins (40ug lysate PSA; FKBP51
and 10ug lysate GAPDH) were loaded onto Invitrogen Bolt™ 4-12% Bis-Tris Plus Precast gels
(Thermo Fisher Scientific). Proteins were separated by electrophoresis, transferred to
Immobilon® -P Polyvinylidene Difluoride Membrane (Millipore Sigma). Membranes were
washed for 5 minutes in 1xTBST, then blocked for 1-hour an appropriate blocking buffer. PSA
5% BSA / 1xTBST and 5% nonfat dry milk in 1xTBS for FKBP51 and GAPDH. Primary
antibodies included: monoclonal anti-PSA/KLK3 D11E1 XP® (1:500; Cell Signaling), mouse
monoclonal anti-FKBP51 Hi51B (1:1000; developed in the lab of Dr. David Smith), and mouse
monoclonal anti-GAPDH (1:3000; loading control; Santa Cruz Biotechnology). Primary
antibodies were diluted in appropriate blocking buffer and allowed to incubate with appropriate
membranes overnight on a shaker at 4°C. The next morning membranes were washed 5 times
with 1xTBST for 5 minutes on a shaker at room temperature. Secondary antibodies consisted of
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alkaline-phosphatase conjugated goat anti-mouse IgG (1:5000; Southern Biotech) and alkalinephosphatase conjugated goat anti-rabbit IgG (1:5000; Southern Biotech), diluted an appropriate
blocking buffer and allowed to incubate with membrane for 1-hour on a shaker at room
temperature. The membranes were washed 5 times with 1xTBST for 5 minutes on a shaker at
room temperature. Membranes were developed with Immuno-Star™ AP substrate (BioRad) and
exposed on CL-X Posure™ film (Thermo Scientific) for detection of antibodies.
VCaP cells were plated at a density of 4.0x105 per well in 24-well tissue culture treated
plates (FALCON®) in 1mL of respective standard growth media modified with 7.5% CS-FBS
and 2.5% FBS, allowed to incubate at 37ºC with 5% CO2. After 48 hours, cells were treated with
PC257 concentrations (0, .1, .5, 1, 10, 25, 50, 75, and 100µM), incubated for 1-hour followed by
500pM DHT. After 24 hours, the cells were washed with PBS at room temperature, followed by
adding 150µL lysis buffer (MPER/Halt) to each well, placed on a shaker for 10 minutes at room
temperature. The cell lysates were collected by centrifugation at 15,000 rpm at 4°C for 20
minutes. In order to determine protein concentration in each sample, Pierce™ Coomassie
(Bradford) Protein Assay Kit (Thermo Scientific) was used. Proteins (30ug lysate PSA; FKBP51
and 10ug lysate GAPDH) were loaded onto Invitrogen Bolt™ 4-12% Bis-Tris Plus Precast gels
(Thermo Fisher Scientific). Proteins were separated by electrophoresis, transferred to
Immobilon® -P Polyvinylidene Difluoride Membrane (Millipore Sigma). Membranes were
washed for 5 minutes in 1xTBST, then blocked for 1-hour an appropriate blocking buffer. PSA
5% BSA / 1xTBST and 5% nonfat dry milk in 1xTBS for FKBP51 and GAPDH. Primary
antibodies included: monoclonal anti-PSA/KLK3 D6B1 XP® (1:1000; Cell Signaling), mouse
monoclonal anti-FKBP51 Hi51B (1:1000; developed in the lab of Dr. David Smith), and mouse
monoclonal anti-GAPDH (1:3000; loading control; Santa Cruz Biotechnology). Primary
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antibodies were diluted an appropriate blocking buffer and allowed to incubate with appropriate
membranes overnight at 4°C. The next morning membranes were washed 5 times with 1xTBST
for 5 minutes on a shaker at room temperature. Secondary antibodies consisted of alkalinephosphatase conjugated goat anti-mouse IgG (1:5000; Southern Biotech) and alkalinephosphatase conjugated goat anti-rabbit IgG (1:5000; Southern Biotech), diluted an appropriate
blocking buffer and allowed to incubate with membrane for 1-hour on a shaker at room
temperature. The membranes were washed 5 times with 1xTBST for 5 minutes on a shaker at
room temperature. Membranes were developed with Immuno-Star™ AP substrate (BioRad) and
exposed on CL-X Posure™ film (Thermo Scientific) for detection of antibodies.
3.5.5 FKBP52 Knockout Cell Pool Identification and Verification
The FKBP4 knockout cell pool was purchased from Synthego, limiting dilution and
clonal expansion was done to produce possible FKBP4 knockouts. Cells were plated at a dilution
concentration of 0.5-1 cell per 100µL of respective standard growth media in 96-well tissue
culture treated plates (FALCON®), allowed to incubate at 37ºC with 5% CO2. The cells were
monitored and visually screened using a microscope in order to establish single colonies for
about a month, anything that was not originated from a single colony was disregarded. Once the
cells reached 70% confluency, the cells were then transferred to a 24-well tissue cultured treated
plate (FALCON®), allowed to incubate at 37ºC with 5% CO2. Once the individual clones had
reached maxima capacity, the cells were transferred to a T-25 filter cap cell culture flask
(CELLSTAR®), allowed to incubate at 37ºC with 5% CO2. Once at 70% confluency the cells were
centrifuged 15,000 rpm at 4°C for 5 minutes, media was discarded and pellet was resuspended in
100µL lysis buffer (MPER/Halt), lysates were collected by centrifugation at 15,000 rpm at 4°C
for 20 minutes. In order to determine protein concentration in each sample, Pierce™ Coomassie
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(Bradford) Protein Assay Kit (Thermo Scientific) was used. Proteins (35ug clone lysate) were
loaded onto Invitrogen Bolt™ 4-12% Bis-Tris Plus Precast gels (Thermo Fisher Scientific).
Proteins were separated by electrophoresis, transferred to Immobilon® -P Polyvinylidene
Difluoride Membrane (Millipore Sigma). Membranes were blocked with 5% nonfat dry milk in
1xTBST for 30 minutes shaking at room temperature. Primary antibodies included: mouse
monoclonal anti-FKBP52 Hi52C (1:1000; recognizes Tail), mouse monoclonal anti-FKBP52
Hi52D (1:5000; recognizes Head), rabbit polyclonal anti-FKBP4 (1:1000; Cell Signaling
Technology®; recognizes the C-terminal Tail). Primary antibodies were diluted in blocking
buffer and allowed to incubate with appropriate membranes overnight at 4°C. The next morning
membranes were washed 5 times with 1xTBST for 5 minutes on shaker at room temperature.
Secondary antibodies consisted of alkaline-phosphatase conjugated goat anti-mouse IgG
(1:5000; Southern Biotech) and alkaline-phosphatase conjugated goat anti-rabbit IgG (1:5000;
Southern Biotech), diluted in blocking buffer and allowed to incubate with membrane for 1-hour
on shaker at room temperature. The membranes were washed 5 times with 1xTBST for 5
minutes on shaker at room temperature. Membranes were developed with Immuno-Star™ AP
substrate (BioRad) and exposed on CL-X Posure™ film (Thermo Scientific) for detection of
antibodies.
An AR-mediated luciferase assay was conducted to demonstrate the differences in
hormone concentration requirements for WT HeLa and 52KO HeLa Clone 6. The 52KO HeLa
Clone 6 cells were co-transfected with FKBP52 to demonstrate when FKBP52 is added back into
the knockout cell line it can reconstitute to wild-type conditions. The cells were plated at 3.0x105
per well in 6-well tissue culture treated plates (FALCON®) in 1.5mL of respective standard
growth media described in section 3.5.1 and allowed to attach at 37°C with 5% CO2. Once cells
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reached 80% confluency, a transient transfection was conducted. The plasmids used for the
experiment were a β-galactosidase expression plasmid (pDS 371, 50ng per well; transfection
control), a hormone-responsive firefly luciferase reporter (pDS 712, 400ng per well), a pCI-Neo
mammalian expression vector expressing AR (pDS 923, 800ng per well), an empty pCI-Neo
mammalian expression vector (pDS 404, 800ng per well, negative control) and a FKBP52 pCINeo mammalian expression plasmid (pDS 600, 800ng per well). The plasmids were transfected
using Lipofectamine® 2000 reagent with a DNA to Lipofectamine® ratio of 1:3 in respective
standard growth media without FBS. Before adding transfection mixture, the 6-well plates were
washed three times with respective standard growth media without FBS. After the third wash,
1mL of respective standard growth media without FBS was added to each well, followed by
500µL of transfection mixture and allowed to incubate for 4-5 hours at 37°C with 5% CO2. After
the transfection incubation, the media was removed and replaced with 1.5mL of respective
growth media modified with 10% CS-FBS. The following day the cells were treated with DHT
concentrations (concentrations did not exceed 0.1%) and allowed to incubate overnight for 16 to
18 hours. The cells were washed with PBS at room temperature followed by adding 150µL lysis
buffer (MPER/Halt) to each well, placed on shaker for 10 minutes at room temperature. The cell
lysates were collected by centrifugation at 15,000 rpm at 4°C for 20 minutes. The cell lysates
were used to measure luciferase expression by using Luciferase assay system (Promega). In an
opaque 96-well plate, 40µL of cell lysate and 100µL of reagent (Luciferase) was added to each
well. The plate was read immediately to measure the relative light units using Synergy 2 MultiMode micro-plate reader (BioTek). The β-galactosidase was measured using Gal Screen® System
(Applied Biosystems). In an opaque 96-well plate, 10µL of cell lysate and 100µL of reagent (βgalactosidase) was added to each well, incubated for 2 hours at room temperature. The plate was
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read to measure relative light units using Synergy 2 Multi-Mode micro-plate reader (BioTek).
The reporter expression was normalized against transfection efficiencies by dividing luciferase
relative light units (RLU) by β-galactosidase relative light units (RLU). The data set represents
an average of three independent experiments. The average EC50 for WT HeLa was 161pM,
52KO HeLa Clone 6 was 5nM and 10pM for FKBP52 reconstituted cells. We have confirmed
that WT HeLa cells require a significant less amount of DHT compared to that of the 52KO
HeLa Clone 6 cells. Therefore, we conducted another AR-mediated luciferase reporter assay
following the same procedures above except we did not do a range of DHT concentrations rather
a single concentration dose with either EtOH or 161pM DHT (the EC50 for the hormone in the
WT HeLa cell line). Based on the data we show that the reconstituted FKBP52 cells restore
efficacy and potency as to that of the WT HeLa cell lines.
To demonstrate the differences in hormone concentration between wild-type and
knockout cell lines, a conformation of androgen receptor induction and FKBP52 induction was
demonstrated via western blot. WT HeLa and 52KO HeLa Clone 6 were plated at 4.0 x 105 per
well in 6-well tissue culture treated plates (FALCON®) in 1.5mL respective growth media
modified with 10% CS-FBS, allowed to incubate at 37ºC with 5% CO2. The next day, the media
was replenished with 1.5mL respective growth media modified with 10% CS-FBS and dosed
with either EtOH, 161pM DHT (WT HeLa) or 3nM DHT (52KO HeLa Clone 6), allowed to
incubate overnight for 16 to 18 hours at 37ºC with 5% CO2. The final EtOH concentration did not
exceed 0.1%. The cells were washed with PBS at room temperature followed by adding 150µL
lysis buffer (MPER/Halt) to each well, placed on shaker for 10 minutes at room temperature. The
cell lysates were collected by centrifugation at 15,000 rpm at 4°C for 20 minutes. In order to
determine protein concentration in each sample, Pierce® Coomassie (Bradford) Protein Assay Kit
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(Thermo Scientific) was used. Proteins (35ug lysate WT HeLa, 52KO HeLa Clone 6 and
GAPDH) were loaded onto Invitrogen Bolt™ 4-12% Bis-Tris Plus Precast gels (Thermo Fisher
Scientific). Proteins were separated by electrophoresis, transferred to Immobilon® -P
Polyvinylidene Difluoride Membrane (Millipore Sigma). Membranes were blocked with 5%
nonfat dry milk in 1xTBS for one hour on shaker at room temperature. Primary antibodies
included: mouse monoclonal anti-AR (1:500; Santa Cruz Biotechnology 441), rabbit polyclonal
anti-FKBP4 (1:1000; Cell Signaling Technology®) and mouse monoclonal anti-GAPDH (1:3000;
loading control; Santa Cruz Biotechnology). Primary antibodies were diluted in blocking buffer
and allowed to incubate with appropriate membranes overnight on shaker at 4°C. The next
morning membranes were washed 5 times with 1xTBST for 5 minutes on shaker at room
temperature. Secondary antibodies consisted of alkaline-phosphatase conjugated goat anti-mouse
IgG (1:5000; Southern Biotech) and alkaline-phosphatase conjugated goat anti-rabbit IgG
(1:5000; Southern Biotech), diluted in blocking buffer and allowed to incubate with membrane
for 1-hour on shaker at room temperature. The membranes were washed 5 times with 1xTBST
for 5 minutes on a shaker at room temperature. Membranes were developed with Immuno-Star™
AP substrate (BioRad) and exposed on CL-X Posure™ film (Thermo Scientific) for detection of
antibodies.
3.5.6 Immunofluorescence
WT 22RV1 cells were plated in Nunc™ Lab-Tek™ chamber slide system at a confluency
of 70% with respective standard growth media and allowed to incubate at 37ºC with 5% CO2 for
18 hours. The cells were then washed twice with PBS followed by respective standard growth
media modified with 10% CS-FBS, allowed to incubate for a minimum of 24 hours at 37ºC with
5% CO2. The cells were than treated with PC257 concentrations (0, 10, 50 and 75µM), incubated
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for 1-hour followed by 300pM DHT (final EtOH and DMSO did not exceed 1%) and allowed to
incubate for 24 hours at 37ºC with 5% CO2. After 24 hours the media was removed carefully and
the fixation process began by adding 400µL of 4% PFA/PBS (Paraformaldehyde Solution, 4% in
PBS) and allowed to incubate at room temperature, covered for 20 minutes. The cells were than
washed three times with PBS for 10 minutes on shaker. Once the washing was complete the
permeabilization process began by adding 400µL of 0.25% Triton® / PBS (ACROS ORGANICS
Thermo Fisher Scientific) and allowed to incubate for 20 minutes, covered at room temperature.
The cells were than washed three times with PBS for 10 minutes on shaker and blocked with 5%
BSA/ PBS (Bovine Serum Albumin Powder, Sigma-Aldrich) for three hours at room
temperature. After blocking, the primary antibody was diluted in 0.1% Triton® / PBS + 1%
BSA/PBS + antibody and allowed to incubate overnight for two days at 4°C. The primary
antibodies included: mouse monoclonal anti-AR (1:60; Santa Cruz Biotechnology), and rabbit
monoclonal anti-FKBP52 (1:500; abcam). After incubation, the cells were washed three times
with PBS for 10 minutes on shaker. The secondary antibody was then diluted in 0.1% Triton® /
PBS + 1% BSA/PBS + antibody and allowed to incubate for two hours at room temperature. The
secondary antibodies included: goat anti-mouse Alexa Fluor® 488 conjugate (1:2000;
Invitrogen™), and donkey anti-rabbit IgG (H+L) Alexa Fluor® Plus 555 (1:2000; Invitrogen™).
The cells were washed three times with PBS for 10 minutes on shaker. Followed by nuclear
staining with DAPI (Santa Cruz Biotechnology) for four minutes. The cells were than washed
three times with PBS for 10 minutes on shaker, chambers were removed, and slide was allowed
to dry. Mounting media (ProLong™ Gold antifade reagent; Invitrogen™) was then placed on
dried slide with coverslip and placed in the 4°C overnight. Slides were analyzed using the Zeiss
Axiovert Fluorescence Microscope.
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3.5.7 Cell Proliferation Assay
WT 22RV1 cells were used to determine PC257 effects on androgen-dependent ARmediated proliferation using CellTiter96® Non-Radioactive Cell Proliferation Assay MTT
(Promega). The cells were plated in a U-shaped 96-well plate at a density of 5x103 cells per well
in 100µL of respective standard growth media modified by replacement of 5% CS-FBS and
incubated for 24 hours at 37ºC with 5% CO2. The cells were treated with a range of PC257
concentrations (10, 30 and 75µM) for one hour followed by the addition of R1881 (1nM) for 24
hours at 37ºC with 5% CO2. The following day 15µL of Dye Solution was added to each well and
incubated at 37ºC with 5% CO2 for 4 hours. After incubation, 100µL of Solubilization/Stop
Solution was added to each well and mixed gently. The absorbance was then recorded at 570nM
using a 96-well plate reader as per manufacturer’s instructions.
3.5.8 Xenograft Mouse Model
The preparation of WT 22RV1 tumor cells, tumor inoculation and PC257 drug treatments
were performed by our collaborators at Clark Atlanta University, Dr. Jaideep Chaudhary. When
the tumors reached an average volume of 100 mm3, the castrated male SCID mice were
randomized into two groups of five mice. The tumor site of each SCID mice was cleaned and
sterilized with an alcohol pad before injection. The test groups were administered either PC257
or co-solvent vehicle without PC257, 5mg/kg intratumorally, twice weekly for a total of five
consecutive weeks. Tumor volumes were recorded prior to each treatment and the castrated male
SCID mice were later sacrificed after five consecutive weeks of vehicle or PC257 treatments.
3.6 RESULTS
The Vancouver Prostate Centre performed an in silico screen against the FKBP52 PPIase
pocket and identified 107 Novel FKBP52-specific hit molecules that target and bind to the
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FKBP52 PPIase pocket. Hit molecules were screened at a single high dose (25µM) for inhibition
of AR activity in MDA-kb2 cell reporter assays. Analogs that inhibited AR activity by 75% or
more were screened in full dose-response curves to determine IC50. Out of the 107 hits identified,
3 of them displayed inhibition of AR activity in the low µM range, with PC257 being the most
potent with an IC50 of 2µM (Figure 3.6.1). Thus, PC257 was then screened in full dose-response
curves for inhibition of GR and PR-regulated activity and at a single high dose of 100µM for
effects on ER-regulated activity (Figure 3.6.2). PC257 inhibited both GR and PR similarly in the
low µM range but did not inhibit ER activity, suggesting that we are targeting FKBP52. As
mentioned before, FKBP52 potentiates AR, GR and PR activities but does not potentiate ER. To
access for FKBP52 specificity in the presence and absence of FKBP52, AR-mediated luciferase
assays were conducted in 52-knockout 22RV1 cell line, 52-knockout mouse embryonic
fibroblast (MEFs) cell line derived from FKBP52 knockout mice, and 52-knockout HeLa cell
line derived from an FKBP4 (FKBP52) knockout cell pool purchased from Synthego (Figure
3.6.3). Although PC257 inhibits AR, GR, and PR similarly, it did not show FKBP52 specificity
in neither knockout (KO) cell line; however, it showed a preference towards FKBP52 over
vector in all knockout cell lines (Figure 3.6.4). Despite the fact that we did not see FKBP52
specificity in these assays, it is likely that targeting the PPIase pockets leads to the targeting of
multiple FKBP proteins simultaneously, which may be therapeutically beneficial. The PPIase
pocket is not only an ideal hydrophobic drug binding pocket but is also highly conserved across
the FKBP family of proteins. Given that the FK506-binding protein 51 (FKBP51) has also been
shown to be a positive regulator of AR in some prostate cancer cell lines (92, 93), it is likely that
determining FKBP52-specific inhibition in a 52KO cell line is complicated by the targeting of
other FKBPs like FKBP51. Thus, FKBP51 is an androgen-regulated gene and modulator of AR
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activity in prostate cancer (94, 95). Not only has evidence shown that FKBP51 levels are
elevated and over-expressed in prostate cancer, but the prostate-specific antigen (PSA) is another
important biomarker used to detect and monitor the disease and response to therapy. The
prostate-specific antigen (PSA) is a serine protease that is secreted exclusively by the prostatic
epithelial cells and is regulated by AR at the transcriptional level (83, 96). Thus, both FKBP51
and PSA are common biomarkers of endogenous, AR-dependent gene expression. Therefore, it
is essential to show that PC257 reduces endogenous levels of FKBP51 and PSA in prostate
cancer cell lines. The effects of PC257 on AR-regulated genes by western blot and densitometry
show PC257 reduces endogenous FKBP51 and PSA expression in a dose-dependent manner in
WT 22RV1, LNCaP, C4-2, and VCaP cells similarly (Figure 3.6.5). In addition, PC257 inhibits
AR-dependent proliferation at concentrations of 30µM and 75µM alone or in combination with
R1881, a synthetic androgen (Figure 3.6.6). Given that previous FKBP52 targeting drugs
inhibited hormone-dependent AR nuclear translocation, we assessed PC257 for inhibition of AR
nuclear translocation in the presence or absence of hormone by immunofluorescent confocal
microscopy. PC257 significantly inhibited hormone-dependent AR translocation to the nucleus.
As previously mentioned, WT 22RV1 cells express both androgen-responsive and androgeninsensitive characteristics. These cells are unique in that they have a full-length AR allele and a
truncated allele that can drive androgen gene expression without hormone. Comparison between
two conditions DHT + DMSO and PC257 at 50µM and 75µM, show a significant reduction of
AR translocation in the nucleus (Figure 3.6.7). If we compare PC257 10µM, 50µM and 75µM
together, the intensity of AR in the nucleus is significantly reduced at 75µM (Figure 3.6.7). In
the presence of EtOH + DMSO, we see an even distribution and very weak signals of AR in the
cytoplasm and nucleus (Figure 3.6.7), which could indicate the signal we see in the nucleus is the
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truncated form of AR. As we compare PC257 (75µM) + DHT to EtOH + DMSO, there is an
even distribution of AR in the cytoplasm and nucleus in treated cells with PC257 (Figure 3.6.7),
confirming that PC257 inhibited AR translocation. The weak signal in the nucleus could be the
truncated form (Figure 3.6.7). In addition, if we compare FKBP52 signal in the DHT + DMSO
treated cells to PC257 (75µM) + DHT, we see a 100 percent reduction of FKBP52 in the nucleus
(Figure 3.6.7). This is also reaffirmed by looking at the red (FKBP52) and green (AR) channels
for colocalization (Figure 3.6.7), confirming that PC257 inhibited the full-length AR allele in the
nucleus. Thus, PC257 effectively inhibits AR translocation into the nucleus in response to
hormone. Although we have assessed the molecular mechanisms of action in cellular models of
prostate cancer, we conducted a pre-clinical evaluation of PC257 in animal models of prostate
cancer in vivo in collaboration with Dr. Jaideep Chaudhary at Clark Atlanta University. Vehicle
control or PC257 was administered intratumorally 5mg/kg, twice weekly and over the period of
five consecutive weeks, the tumor growth on the castrated male SCID mice had decreased when
compared to vehicle control (Figure 3.6.8).
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Figure 3.6.1: Identification of Novel FKBP52-Specific Hit Compounds

Structure-based drug design methodology and in silico library screening was used to identify 107
molecules targeting the FKBP52 PPIase pocket. Molecules were assessed for the ability to
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inhibit AR-mediated luciferase expression at a single high concentration (25µM) in MDA-kb2
cells. Molecules that showed inhibition at 25µM were assessed in full dose-response curves to
determine the IC50. MDA-kb2 cells were treated with 200pM DHT with a range of derivative
concentrations.
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Figure 3.6.2: PC257 Inhibits FKBP52 Specific AR-, GR-, and PR-Mediated Activity

PC257 inhibits FKBP52 AR-, GR-, and PR-mediated activity. A. An in silico screen identified a
total of 107 hits. Molecules were screened at a single high dose of 25µM, incubated, then treated
with 200pM DHT to assess inhibition of AR activity in MDA-kb2 cells. B. MDA-kb2 cells were
treated in a range of PC257 concentrations (0, .01, .1, 1, 10, 25, 50, and 100µM) incubated,
treated with 200pM DHT to assess AR-dependent activity. C. MDA-kb2 cells were treated with
PC257 concentrations (0, .01, .1, 1, 10, 25, 50, and 100µM) incubated, treated with 50nM DEX
to assess GR-dependent activity. D. HeLa cells were used to test for FKBP52 PR-mediated
activity. The cells were treated in a range of PC257 concentrations (0, .01, .1, 1, 10, 25, 50, and
100µM) incubated, treated with 4nM P4 to assess PR-dependent activity. E. T47D-KBluc cells
were used to assess the effects of PC257 on ER-regulated activity. Cells were treated with a
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single high dose of PC257 (100µM), incubated, dosed with 10pM E2. All data sets are
represented as Mean ± SD of an average of three independent experiments.
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Figure 3.6.3: Identification of HeLa FKBP4 Knockout Cell Pool

The Identification of an FKBP4 knockout. A. Through limited dilution and clonal expansion,
five clones were identified for the potential of having FKBP52 knocked out. The lysates from the
potential clones were electrophoresed and immunoblotted for the presence or absence of
FKBP52. B. WT HeLa and 52KO HeLa Clone 6 lysates were grown in the presence or absence
of DHT (161pM and 3nM, the EC50 for the corresponding cell line respectively), electrophoresed
and immunoblotted for AR, FKBP52 and GAPDH (loading control). C. WT HeLa and 52KO
HeLa Clone 6 cells were transiently transfected with a β-galactosidase expression plasmid, a
hormone-responsive firefly luciferase reporter, an empty pCI-Neo mammalian expression vector
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and/or FKBP52 pCI-Neo mammalian expression plasmid. The cells were treated in the presence
and absence of DHT (161pM, the EC50 for the hormone in the WT HeLa cells) incubated for 16
to 18 hours. D. WT HeLa and 52KO HeLa Clone 6 cells were transiently transfected with the
plasmids above. Treated in a range of DHT concentrations and incubated. The final hormone
concentration for WT HeLa is 161pM, 52KO HeLa 5nM and 10pM for FKBP52 reconstituted
cells. The western blots are a representation of three independent experiments and the reporter
assays represent an average of three independent experiments in which the EtOH concentration
did not exceed 0.1%.
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Figure 3.6.4: PC257 Shows Preference for FKBP52 Specific AR-Mediated Activity in 52KO
Cell Lines

The knockout cell lines were used to assess for FKBP52 specificity in the presence and absence
of FKBP52. A. 52KO 22RV1 cells were treated in a range of PC257 concentrations (0, .001, .01,
.05, .1, .5, 1, 10 and 100µM) incubated, then treated with 100pM DHT and 4nM DHT. B. 52KO
HeLa cells were treated in a range of PC257 concentrations (0, .001, .01, .05, .1, .5, 1, 10 and
100µM) incubated, then treated with 100pM DHT and 4nM DHT. C. 52KO MEFs were treated
in a range of PC257 concentrations (0, .001, .01, .05, .1, .5, 1, 10 and 100µM) incubated, then
treated with 10pM DHT and 1nM DHT, incubated overnight for 16 to 18 hours. The ARmediated reporter assays represent an average of three independent experiments.
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Figure 3.6.5: PC257 Reduces AR-dependent Endogenous Gene Expression in Prostate Cancer
Cell Lines

WT 22RV1, LNCaP, C4-2 and VCaP cells were used to assess PC257 effects on AR-dependent
endogenous expression by western immunoblots. The cells were treated in a range of PC257
concentrations (0, .1, .5, 1, 10, 25, 50, 75, and 100µM) incubated, treated with DHT and
incubated for 24 hours. Lysates were electrophoresed and immunoblotted for FKBP51, PSA and
GAPDH (loading control). The immunoblots are a representation of four independent
experiments for each cell line. The lower panel represents the averaged protein levels that were
quantified via densitometry from four independent experiments. Image J assisted in the
normalization of protein levels to GAPDH (loading control) followed by normalized set to 100%
(DHT only). The average of the four independent experiments for each cell line was calculated
by one-way ANOVA followed by Bonferroni’s multiple comparison test compared with control.
Analysis shows a statistically significant difference compared to control (DHT only) with a Pvalue of ****P≤ 0.0001.
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Figure #: PC257 Inhibits AR-dependnent Proliferation in WT 22RV1 Cell Lines. PC257 Inhibits proliferation weather hormone is present or not. A. The
cells were treated with 10uM PC257 incubated for one hour followed by 1nM R1881. B. The cells were treated with 30uM PC257 incubated for one hour followed
by 1nM R1881, PC257 (30uM) alone and in combination with R1881 inhibits proliferation when compared to vechicle control. C. Cells were treated with 75uM
PC257 incubated for one hour followed by 1nM R1881, the same effect is aparent with PC257 (75uM) alone and in combination with R1881. The absorbance
was measured at 570 nM using a 96-well plate reader.The data representations three independent experiments.

Figure 3.6.6: PC257 Inhibits AR-dependent Proliferation in WT 22RV1 Cell Lines

PC257 effectively abrogates prostate cancer cell proliferation. A. The cells were treated with
10µM PC257, incubated, followed by 1nM R1881. B. The cells were treated with 30µM PC257,
incubated, followed by 1nM R1881. PC257 (30µM) alone and in combination with R1881
inhibits proliferation when compared to vehicle control. C. Cells were treated with 75µM PC257,
incubated, followed by 1nM R1881, the same effect is apparent with PC257 (75µM) alone and in
combination with R1881. The absorbance was measured at 570nM using a 96-well plate. The
data is a representation of three independent experiments.
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Figure 3.6.7: PC257 Alters Full-Length AR Signaling, and Nuclear Translocation in WT 22RV1
Cells Via Immuno-Fluorescence Analysis

WT 22RV1 cells were analyzed before and after treatment with DHT and PC257. The
interactions inside the cell effectively show that PC257 with the presence of DHT blocked
translocation of AR (green) and FKBP52 (red) to the nucleus (blue; DAPI). In the presence of
only DHT, AR (green) translocates to the nucleus but in the presence of PC257 (range of
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concentrations) AR (green) is inhibited and remains in the cytoplasm, but the truncated form
translocates to the nucleus. The data is a representation of 3 independent experiments.
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Figure #: The Effects of PC257 Treatment on Tumor Growth in WT 22RV1 Cells in vivo. Castrated male SCID mice were randomized into two groups of 5 mice.
The tumor (WT 22RV1) volumes of PC257 treatment and/ or untreated tumors were measrued weekly (mm3). Vechicle (10% DMSO) or PC257 were administered
intratumoral 5mg/kg, twice weekly for a total of five consecutive weeks. In the five consecutive weeks PC257 inhibits tumor growth in WT 22RV1cells, the
castrated male SCID mice were sacrificed after five consecutive weeks of vehicle or PC257 treatments.
Lorem ipsum

Figure 3.6.8: The Effects of PC257 Treatment on Tumor Growth in WT 22RV1 Cells in Vivo

Castrated male SCID mice were randomized into two groups of five mice. The tumor (WT
22RV1) volumes of PC257 treatment and/ or untreated tumors were measured weekly (mm3).
Vehicle (10% DMSO) or PC257 were administered intratumorally 5mg/kg, twice weekly for a
total of five consecutive weeks. In the five consecutive weeks PC257 inhibits tumor growth in
WT 22RV1 cells, the castrated male SCID mice were sacrificed after five weeks of vehicle or
PC257 treatments.
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3.7 DISCUSSION
We have identified a completely new chemotype independent of GMC1, known as
PC257. As previously mentioned, the proline-rich loop surface that overhangs the FKBP52
PPIase pocket is essential and likely represents an AR interaction surface. Therefore, we wanted
to identify specific PPIase binding molecules that reorient the proline-rich loop when docked in
the pocket leading to the disruption of FKBP52 interactions. An in silico structure-based drug
design identified novel FKBP52-specific hits for functional screening that targeted the FKBP52
PPIase pocket. We identified PC257 that displayed FKBP52-specific inhibition of AR, GR, and
PR- activity similarly in the low µM range but not ER activity. We wanted to show that PC257
specifically inhibited FKBP52 regulated AR activity in the presence of FKBP52 in various
knockout cell lines but what we encountered is that PC257 regulates AR activity in the presence
and absence of FKBP52; however, shows a slight preference towards FKBP52. The fact that the
PPIase pocket is a conserved, known “druggable” pocket for all FKBPs, suggests that PC257
may be targeting multiple FKBPs simultaneously and not just FKBP52. PC257 reduces ARdependent endogenous gene expression, AR-dependent proliferation, AR translocation to the
nucleus, and pre-clinical animal studies displayed inhibition of tumor growth as compared to
vehicle control over a period of five consecutive weeks in castrated male SCID mice. We have
identified a new chemotype predicted to target the FKBP52 PPIase pocket to inhibit FKBP52regulated AR activity in prostate cancer. The fact that PC257 specifically inhibits FKBP52regulated receptors but not ER supports the idea that PC257 targets FKBP52. In addition, PC257
showed a preference for 52-regulated AR activity in the 52KO cellular models. Finally, in initial
animal evaluations, PC257 significantly inhibited tumor growth as compared to vehicle controls.
Further studies will aim to conduct a hit-to-lead optimization to identify PC257 analogs with
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increased potency and solubility. More detailed animal studies will be reserved for optimized
PC257 analogs identified in the future.
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Chapter 4: Drug Combination Therapies with Classic Anti-Androgens and β-Blockers
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4.1 RATIONALE
Limited and insufficient studies have been conducted to demonstrate the correlation
between β-blockers (Propranolol and Carvedilol) combined with current anti-androgens to treat
prostate cancer. Combination therapies using anti-cancer drugs have emerged as a promising
approach for the therapeutic targeting of CRPC with the potential of reducing drug resistance.
Emerging evidence suggests that there is an increased benefit of cancer drugs when given in
combination with β-blockers. The National Cancer Institute is in phase II clinical trials to
determine whether Carvedilol, given before surgery, impacts prostate cancer growth or
progression for individuals undergoing surgery to remove the prostate (97). Studies have shown
that Propranolol has exhibited synergistic effects or synergism with drugs that affect multiple
drug-resistant transporters leading to an increased drug in the cell (82). Research by Brohee et al.
(82) found that Propranolol in combination with a glycolysis inhibitor 2DG effectively prevented
prostate cancer cell proliferation. As a result, we took two β-blockers and tested them in
combination with MDV3100 (a classic anti-androgen) and our drug MJC13. Our objective,
therefore, aimed to identify unique drug combinations using β-blockers and anti-androgens as a
strategy to overcome treatment resistance to currently used drugs for CRPC.
4.2 STATISTICAL ANALYSIS
GraphPad Prism 8.4.2 was used to make all graphs. All data sets are represented as Mean
± SD of an average of three independent experiments. The final EtOH and DMSO concentrations
did not exceed 1%.
4.3 MATERIAL AND METHODS
4.3.1 Cell Culture
Refer to previous chapter 2 and section 2.4 for maintenance on MDA-kb2 cell lines.
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4.3.2 Mammalian Cell Based Luciferase Assay
To determine the IC50 for MDV3100, MJC13, Carvedilol, and Propranolol. MDA-kb2
cells were used for the Bright-Glo™ Luciferase assay system (Promega) to determine ARdependent activity. The cells were plated at 4.5x104 cells per well in a 96-well luminometer plate
(Costar® 3610) in 100µL of Hyclone™ Leibovitz’s L-15 with supplemental 10% FBS and
allowed to attach at 37°C without CO2. Once attached, the cells were washed three times with
Hyclone™ Leibovitz’s L-15 with supplemental 10% CS-FBS. After the third wash, 100µL of
media containing 10% CS-FBS was added and allowed to incubate overnight at 37°C without
CO2. After 24 hours, the cells were dosed with DMSO + EtOH (negative control), DMSO plus
the agonist (DHT 200pM; positive control), followed by a range of compound (Propranolol,
Carvedilol, MJC1, and MDV3100) concentrations, incubated for 30 minutes at 37°C without CO2.
Once the incubation was complete, the agonist (DHT 200pM) was added to all wells containing
compounds, incubated for 16-20 hours at 37°C without CO2. The luciferase reporter assay was
performed by adding 100µL of reagent (Bright- Glo™) to each well, then reading the plate after
4 minutes. Relative light units (RLU) per well were determined using Synergy 2 Multi-Mode
micro-plate luminometer reader (BioTek); each concentration was assayed independently with
duplicate wells for every assay.
4.3.3 Propranolol (10µM), MJC13, MDV3100
To assess drug combination effects on AR-dependent activity, MDA-kb2 cells were used
for the Bright-Glo™ luciferase assay system (Promega). AR agonist (DHT) was used to induce
AR-mediated luciferase expression. The cells were plated at 4.5x104 cells per well in a 96-well
luminometer plate (Costar® 3610) in 100µL of Hyclone™ Leibovitz’s L-15 with supplemental
10% FBS and allowed to attach at 37°C without CO2. The next day, the cells were washed three
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times with Hyclone™ Leibovitz’s L-15 with supplemental 10% CS-FBS. After the third wash,
100µL of 10% CS-FBS was added and allowed to incubate overnight at 37°C without CO2. Before
dosing, drug combinations were prepared: a range of MJC13 concentrations (0, .00001, .0001,
.0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM) was made to hold a total volume of
99µL, then 1µL Propranolol (10µM) was added to the MJC13 concentrations making it a total
volume of 100µL, the same procedure was followed for MDV3100. The 96-well plate was dosed
with DMSO + EtOH (negative control), DMSO plus the agonist (DHT 200pM; positive control)
followed by a range of MJC13 + Propranolol concentrations and MJC13 alone, or MDV3100 +
Propranolol concentrations and MDV3100 alone, incubated for 30 minutes, then added agonist
(DHT 200pM) to all wells and allowed to incubate for 16-20 hours at 37°C without CO2. The
luciferase reporter assay was performed by adding 100µL of reagent (Bright- Glo™) to each
well, then reading the plate immediately. Relative light units (RLU) per well were determined
using Synergy 2 Multi-Mode micro-plate luminometer reader (BioTek); each concentration was
assayed independently with duplicate wells for every assay.
4.3.4 Propranolol (65µM), Carvedilol (7µM), MJC13, MDV3100
MDA-kb2 cells were used for the Bright-Glo™ luciferase assay system (Promega). The
cells were plated at 4.5x104 cells per well in a 96-well luminometer plate (Costar® 3610) in
100µL of Hyclone™ Leibovitz’s L-15 with supplemental 10% FBS and allowed to attach at 37°C
without CO2. The next day, the cells were washed three times with Hyclone™ Leibovitz’s L-15
with supplemental 10% CS-FBS. After the third wash, 100µL of 10% CS-FBS was added and
allowed to incubate overnight at 37°C without CO2. The 96-well plate was dosed with DMSO +
EtOH (negative control), DMSO plus the agonist (DHT 200pM; positive control) followed by
.1µL Propranolol (65µM) incubated for 30 minutes, then .9µL MJC13 concentrations (0, .00001,
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.0001, .0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM); as a control MJC13 alone, or
MDV3100 concentrations (0, .00001, .0001, .0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and
100µM); as a control MDV3100 alone and allowed to incubate for 30 minutes followed by
agonist (DHT 200pM) and allowed to incubate for 16-20 hours at 37°C without CO2. The
luciferase reporter assay was performed by adding 100µL of reagent (Bright- Glo™) to each
well, then reading the plate immediately. Relative light units (RLU) per well were determined
using Synergy 2 Multi-Mode micro-plate luminometer reader (BioTek); each concentration was
assayed independently with duplicate wells for every assay. The same procedure was followed
for drug combination Carvedilol + MJC13 and Carvedilol + MDV3100 by adding .1µL
Carvedilol (7µM), incubate 30 minutes, add .9µL MJC13 concentrations or MDV3100
concentrations, incubate 30 minutes followed by agonist.
4.3.5 MJC13 (5µM) and MDV3100 (450nM)
MDA-kb2 cells were used for the Bright-Glo™ luciferase assay system (Promega). The
cells were plated at 4.5x104 cells per well in a 96-well luminometer plate (Costar® 3610) in
100µL of Hyclone™ Leibovitz’s L-15 with supplemental 10% FBS and allowed to attach at 37°C
without CO2. The next day, the cells were washed three times with Hyclone™ Leibovitz’s L-15
with supplemental 10% CS-FBS. After the third wash, 100µL of 10% CS-FBS was added and
allowed to incubate overnight at 37°C without CO2. The 96-well plate was dosed with DMSO +
EtOH (negative control), DMSO plus the agonist (DHT 200pM; positive control) followed by
.1µL MJC13 (5µM) incubated for 30 minutes, then .9µL MDV3100 concentrations (0, .00001,
.0001, .0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM) and as a control MDV3100
alone, allowed to incubate for 30 minutes followed by agonist (DHT 200pM) and allowed to
incubate for 16-20 hours at 37°C without CO2. The luciferase reporter assay was performed by
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adding 100µL of reagent (Bright- Glo™) to each well, then reading the plate immediately.
Relative light units (RLU) per well were determined using Synergy 2 Multi-Mode micro-plate
luminometer reader (BioTek); each concentration was assayed independently with duplicate
wells for every assay. The same procedure was followed for drug combination MDV3100 +
MJC13 except .1µL of MDV3100 (450nM) was incubated for 30 minutes, followed by .9µL of
MJC13 concentrations (listed above) and as a control MJC13 alone, incubate 30 minutes
followed by agonist.
4.4 RESULTS
The drug combination therapy involved a total of four drugs, two of which are FDAapproved β-blockers (Propranolol and Carvedilol) that treat high blood pressure in addition to
other conditions. MDV3100 is an FDA-approved drug to treat CRPC and recently metastatic
castration-resistant prostate cancer that binds directly to the AR hormone binding pocket and
competitively inhibits androgen binding. MDV3100 is unique among the classic anti-androgens
in that it inhibits AR nuclear translocation. MJC13 is not FDA-approved but targets AR
regulation by binding to the BF3 surface and has effectively been shown to block AR signaling
and AR nuclear translocation. The IC50 of Propranolol, Carvedilol, MJC13, and MDV3100 was
determined by performing an AR-mediated luciferase assay in MDA-kb2 cell lines (Figure 4.4.1
A). The IC50 for Propranolol was determined to be at 65µM; therefore, we conducted an ARmediated luciferase assay to test Propranolol (65µM) combined with a range of doses of
MDV3100 (Figure 4.4.1 B) or MJC13 (Figure 4.4.1 C), and, as controls, MDV3100 or MJC13
alone. Propranolol (65µM) in combination with MDV3100 or MJC13 effectively increased
efficacy and potency (Figure 4.4.1 B and C). To determine if the effects we saw were due to
Propranolol alone or in combination with MDV3100 and or MJC13, we tested Propranolol at a
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non-effective dose. An AR-mediated luciferase assay was conducted to test Propranolol (10µM)
in combination with MDV3100 (Figure 4.4.1 D) and or MJC13 (Figure 4.4.1 E) and as a control
MDV3100 and or MJC13 alone. Propranolol at 10µM, a non-effective dose, slightly increases
efficacy and potency in combination with MDV3100 and MJC13. The same effect is visualized
when Carvedilol (7µM) in combination with MJC13 (Figure 4.4.2 A) and or MDV3100 (Figure
4.4.2 B) are combined, showing an increase in efficacy and potency. These data suggest that the
combination of β-blockers with anti-androgens can serve as an alternative approach for drug
combination therapies. In addition to the β-blockers, we also tested MDV3100 (450nM) in
combination with MJC13 (Figure 4.4.3 A) and or MJC13 (5µM) in combination with MDV3100
(Figure 4.4.3 B). There was a significant decrease in efficacy in both cases but an increase in
potency with MDV3100 + MJC13 compared to MJC13 alone and a decrease in potency with
MJC13 + MDV3100 compared to MDV3100 alone.
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Figure 4.4.1: Optimizing Drug Synergy Effects for Propranolol in Combination with MJC13 and
MDV3100 in AR-Mediated Luciferase Assays

Compared to MJC13 or MDV3100 alone, Propranolol in combination with either one at an IC50
of 65µM and/or 10µM showed a slight synergy increase in potency and increase in efficacy. A.
The IC50 of each drug was determined to optimize combination effects. MDA-kb2 cells were
treated in a range of drug concentrations (0, .0001, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and
100µM), incubated then treated with DHT. B. MDA-kb2 cells were treated with Propranolol
(65µM), incubated, treated with a range of MDV3100 concentrations (0, .00001, .0001, .0005,
.001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM), incubated, then treated with DHT. As a
control MDA-kb2 cells were treated alone with MDV3100 concentrations. C. MDA-kb2 cells
were treated with Propranolol (65µM), incubated, treated with a range of MJC13 concentrations
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(listed above), incubated, then treated with DHT. As a control MDA-kb2 cells were treated alone
with MJC13 concentrations. D. A range of MJC13 concentrations (0, .00001, .0001, .0005, .001,
.005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM) plus Propranolol (10µM) were added to each well,
incubated, followed by DHT. E. The same procedure was followed as in Figure D except with
MDV3100 concentrations. The data represent three independent experiments.
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Figure 4.4.2: Dose Effects with Carvedilol in Combination with MJC13 and MDV3100

The effects of two different drugs in combination with Carvedilol show a synergistic
combination effect with an increase in potency and efficacy. A. MDA-kb2 cells were treated
with Carvedilol (7µM), incubated, treated with a range of MJC13 concentration (0, .00001,
.0001, .0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM), incubated, then treated with
DHT. As a control MDA-kb2 cells were treated with a range of MJC13 concentrations (listed
above), incubated and treated with DHT. B. MDA-kb2 cells were treated with Carvedilol (7µM),
incubated, treated with a range of MDV3100 concentration (listed above), incubated, treated
with DHT. As a control cells were treated with a range of MDV3100 concentrations (listed
above), incubated then treated with DHT. The data represent three independent experiments.
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Figure 4.4.3: Androgen Receptor Antagonist Drug Combination Therapy

MJC13 and MDV3100 drug combination display a significant decrease in efficacy than when
administered separately in AR-mediated luciferase assays. A. MDA-kb2 cells were treated with
MDV3100 (450nM), incubated, treated with a range of MJC13 concentration (0, .00001, .0001,
.0005, .001, .005, .01, .05, .1, .5, 1, 5, 10, 50, and 100µM), incubated, treated with DHT. As a
control MDA-kb2 cells were treated with a range of MJC13 concentrations (listed above),
incubated, treated with DHT. B. MDA-kb2 cells were treated with MJC13 (5µM) incubated,
treated with a range of MDV3100 concentration (0, .00001, .0001, .0005, .001, .005, .01, .05, .1,
.5, 1, 5, 10, 50, and 100µM), incubated, treated with DHT. As a control MDA-kb2 cells were
treated with a range of MDV3100 concentrations (listed above), incubated, treated with DHT.
The data represent three independent experiments.
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4.5 DISCUSSION
Current treatment with anti-androgens and β-blockers, such as Propranolol and
Carvedilol, have not been extensively utilized to maximize their full potential when combined
for therapeutics. Present-day PCa treatment involves anti-androgens that compete for androgen
binding by binding to the androgen receptor, preventing the formation of a functional AF2
pocket (18). We have demonstrated in figure 1.5.5 that targeting FKBP52 would have several
advantages over current Hsp90 inhibitors and anti-androgens used to treat early-stage prostate
cancer. Inhibiting FKBP52 would inhibit AR, GR, and PR activity and NF-kB transcriptional
activity, which has been shown to promote AR splice variant expression in CRPC (98).
Moreover, inhibition of NF-kB by Carvedilol has also been observed in human mononuclear
cells (85). For that reason, the characterization of combinatorial drug effects in cellular models of
prostate cancer with PC257, GMC1, MJC13, classic anti-androgens, and β-blockers needs to be
significantly explored. Furthermore, drug combination therapy with classic anti-androgens (e.g.,
MDV3100) and our novel FKBP52/AR targeting drugs (e.g., MJC13 and GMC1) have not been
explored. Propranolol and Carvedilol combined with MDV3100 or MJC13 at the IC50 or a noneffective dose effectively increased potency compared to the anti-androgens alone. The drugdrug interactions observed could result from β-blockers increasing drug availability in the cell by
blocking or slowing the rate of drug transport out of the cell. In addition, MDV3100 (classic antiandrogen) combination with our novel FKBP52/AR targeting drug, MJC13, displayed significant
drug-drug interactions as maximum AR activity in the presence of hormone was reduced
significantly. There may be some therapeutically beneficial drug-drug interactions between βblockers with PC257, GMC1, MJC13, and classic anti-androgen that can be explored in more
detailed future studies, not only in cells but also in animals.
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Chapter 5: Conclusion
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5.1 METHODOLOGICAL CHALLENGES AND CONSIDERATIONS
While others have focused on the development to improve anti-androgens and the
blockade of steroidogenesis, a strategy that exploits the dependence of AR for the treatment of
PCa, our lab has pursued a unique non-AR strategy that targets novel AR co-regulators for the
treatment of PCa. Several co-activators, chaperones, and cochaperones serve as potential
therapeutic targets to block AR activity. Inhibiting or blocking the function of these androgen
receptor co-activators and cochaperones renders the androgen receptor non-functional. The drugs
developed here are the first-in-class for the direct targeting of an androgen receptor-associated
cochaperone to treat castration-resistant prostate cancer.
We have pursued the therapeutic targeting of a novel cochaperone known to be critical
for androgen receptor signaling. The cochaperone FK506 binding protein 52kDa (FKBP52)
represents a promising non-AR therapeutic target for disrupting several mechanisms important in
PCa. FKBP52 shows specificity for a small subset of Hsp90 client proteins and regulates
multiple, distinct steps within the AR signaling pathway, some of which are independent of
Hsp90 (18, 48). Consequently, direct targeting of FKBP52 will inhibit beta-catenin, FKBP51,
and 52-dependent potentiation of AR, GR, and PR activity (18, 66).
As previously mentioned, our lab developed a molecule known as MJC13 that targets the
AR BF3 surface that serves as a promiscuous regulatory surface for a number of co-regulators,
including FKBP52, as described in section 1.5.2 (49). Given that MJC13 targets the AR BF3
surface, it does not affect the activity from the truncated constitutively active AR variant (V7)
co-expressed with full-length AR in CRPC (49, 66). Our data has shown that direct targeting of
FKBP52 offers several advantages over MJC13. The AR BF3 surface is not an ideal drugbinding site, and molecules docked on this surface can be easily replaced. However, the FKBP52
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PPIase pocket is not only an ideal hydrophobic drug-binding pocket, but it is the PPIase pocket
of all FKBPs and is a known “druggable target” based on data gathered in studies with FDAapproved Tacrolimus (18, 48, 51). Targeting FKBP52 directly will inhibit not only FKBP52
regulation of AR, GR, PR, and NF-kB but also inhibit beta-catenin regulation of AR and hit
multiple proteins in prostate cancer simultaneously, including the truncated constitutively active
AR variant (V7) that is co-expressed with full-length AR (66).
We have identified novel FKBP52 inhibitors, PC257 and GMC1, that target the PPIase
pocket, disrupting FKBP52 proline-rich loop conformation leading to the disruption of FKBP52
interactions within the steroid hormone receptor heterocomplex. This disruption effectively
inhibited AR, GR, PR signaling, PCa cell proliferation, AR-dependent endogenous gene
expression, nuclear translocation, and prostate tumor formation. Not only has PC257 emerged as
a promising therapeutic for CRPC, but it has also been shown to be effective against SARSCoV-2 infection in cells (data not shown), Dr. Manual Llano at The University of Texas at El
Paso. We hypothesize that PC257 inhibits TMPRSS2 gene expression (an essential proteins for
SARS-CoV-2 infection), in addition to potentially affecting the chaperoning of viral proteins.
Further studies in both cells and animal models are needed to elucidate the mechanism of action.
Our lab is the first to develop drugs that directly target a receptor-associated cochaperone to treat
CRPC. This unique mechanism of action has the ability to bypass the agonistic effects that result
from targeting the hormone-binding pocket, improving the quality of life in patients diagnosed
with CRPC. Our drugs alone or in combination with existing therapeutics (β-blockers, antiandrogens, SARs-Covid 2 infection) provide options for the design of individualized and/or
combination therapies that would reduce prostate cancer growth and lead to a more effective
drug for the treatment of CRPC.

100

5.2 FUTURE DIRECTION
5.2.1 GMC1
Although 97 GMC1 analogs were produced, only two of those showed the best PK/PD
properties with high metabolic stability, intestinal permeability, and slightly better solubility.
More chemistry work is needed to improve GMC-M-V27, and we will continue to work
alongside MAIA biotechnology. We want to ensure that new GMC-based analogs move towards
securing investigational new drug status in preparation for phase I trials in the future. This can be
achieved by chemically modifying GMC-M-V27 and characterizing its drug effects in prostate
cancer cellular.
5.2.2 PC257
We have identified a novel FKBP52-specific hit, PC257, in addition to characterizing the
mechanism of action and generated early preclinical data in cellular and xenograft mouse models
of prostate cancer. It is important to note that PC257 has not yet been optimized, and further
characterization needs to be conducted, such as verifying the drug binding site by performing
functional mutagenesis on the FKBP52 PPIase pocket and showing that FKBP52 regulation of
AR remains unimpaired and performing a PSA secretion ELISA assay in a variety of prostate
cancer cell lines. Execute PK/PD properties, ADME properties, co-solvent formulation, seek IP
and patent protection, and conduct a hit-to-lead optimization with the chemistry help of MAIA
biotechnology with the goal of increasing efficacy, reducing toxicity, and ensuring
bioavailability of the compound.
5.2.3 Drug Combination Therapy with β-blockers
We have pursued a unique combinatorial therapy with current anti-androgens and βblockers that have not been explored in PCa. We know that Propranolol and Carvedilol alone
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have the potential to treat cancers like angiosarcoma and breast cancer. Until now, we have
shown that β-blockers in combination with anti-androgens have the potential to treat PCa.
Further characterization and analysis need to be conducted to determine if the effects shown
result from general effects on transcription, translation, or protein stability and not only specific
to AR-dependent transcription. In addition, the inhibition of AR-dependent and AR-independent
activity needs to be assessed in prostate cancer cell models. Furthermore, GMC1 and PC257 are
promising therapeutics in combination with β-blockers because they are a non-AR based strategy
that targets FKBP52.
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Glossary
52 KO MEF- fkbp52- deficient mouse embryonic fibroblast
ADME- Absorption, distribution, metabolism and excretion
ADP- Adenosine diphosphate
AF1- Activation function 1
AF2- Activation function 2
ANOVA- Analysis of variance
AP- Alkaline phosphatase
AR- Androgen receptor
AR-V7- AR-splice variant 7
ARE- Androgen response elements
ATCC- American type culture collection
ATP- Adenosine triphosphate
BAG-1- Bcl-2- associated athanogene
BF3- Binding function 3
BSA- Bovine serum albumin
CHIP- Carboxyl terminus of Hsp70-interacting protein
CKII- Casein Kinase II
CO2- Carbon dioxide
CRPC- Castration resistant prostate cancer
CS- Charcoal stripped
Cyp40- Cyclophilin 40
DBD- DNA binding domain
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DEX- Dexamethasone
DHT- 5a-dihydrotestosterone
DMEM- Dulbecco’s modified eagle medium
DMSO- Dimethyl sulfoxide
E2- 17β-estradiol
EC50- Half maximal effective concentration
ER- Estrogen receptor
ERa- Estrogen receptor alpha
ERb- Estrogen receptor beta
ERE- Estrogen response element
EtOH- Ethanol
FBS- Fetal bovine serum
FKBP12- 12-kDa FK506-binding protein
FKBP4- FKBP52
FKBP51- 51-kDa FK506-binding protein
FKBP52- 52-kDa FK506-binding protein
GAPDH- Glyceraldehyde-3-phosphate dehydrogenase
GR- Glucocorticoid receptor
Halt- Protease inhibitor single-use cocktail EDTA-free
HIP- Hsp interacting protein
HOP- Hsp organization protein
HRE- Hormone response element
Hsp40- Heat shock protein 40 kDa
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Hsp70- Heat shock protein 70 kDa
Hsp90- Heat shock protein 90
IC50- Half maximal inhibitory concentration
IND- Investigational new drug application
KO- Knockout
LBD- Ligand binding domain
LBP- Ligand binding pocket
M-PER- Mammalian protein extraction reagent
MEM-NEAA- MEM-nonessential amino acids
MEM/EBSS- Minimal essential media/Earle’s balanced salt solution
MMTV- Mouse mammary tumor virus
MR- Mineralocorticoid receptor
NLS- Nuclear localization signal
NTD- N-terminal domain
p23- Protein 23 kDa
P4- Progesterone
PBS- Phosphate buffered saline
PCa- Prostate cancer
PCR -Polymerase chain reaction
PFA- Paraformaldehyde solution
PPIase- Peptidyl-prolyl cis/trans isomerase
PR- Progesterone receptor
PSA- Prostate specific antigen
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RLU- Relative light unit
RNP- Ribonucleoprotein
SAR- Structure activity relationship analysis
SD- Standard deviation
SHR- Steroid hormone receptor
SRC-2- Steroid receptor co-activator 2
TBS- Tris-buffered saline
TBST- Tris-buffered saline containing tween
TPR- Tetratricopeptide repeat
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